Application of semaphorin-4D inhibitory molecules combined with immunomodulatory therapy to inhibit tumor growth and metastasis
A binding molecule targeting SEMA4D, combined with immunomodulatory therapies, addresses the challenge of tumor growth and metastasis by enhancing treatment efficacy through immune modulation.
Patent Information
- Application Number
- CN201480047166.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2013-11-22
- Filing Date
- 2014-06-20
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2034-06-20
AI Technical Summary
Current cancer treatments lack effective single agents or combination therapies that can inhibit, reduce, or prevent tumor growth and metastasis by targeting semaphorin-4D (SEMA4D) signaling pathways.
Administering an isolated binding molecule that specifically binds to SEMA4D, combined with immunomodulatory therapies such as cancer vaccines, immunostimulants, or immune checkpoint blockers, to inhibit SEMA4D-mediated signaling and enhance therapeutic efficacy.
The combination therapy effectively inhibits tumor growth and metastasis by modulating immune cell infiltration and organization, demonstrating enhanced therapeutic outcomes compared to individual treatments.
Smart Images

Figure CN105492016B_ABST
Abstract
Description
[0001] Reference to Submitted Sequence Listing
[0002] The contents of the electronically submitted text file Sequence Listing submitted with the present application (name: 58008_133124_SEQ_LST.txt; size: 37,171 bytes; and creation date: June 20, 2014) are incorporated herein by reference in its entirety.
[0003] background
[0004] Semaphorin 4D (SEMA4D), also known as CD100, is a transmembrane protein belonging to the semaphorin gene family (e.g., SEQ ID NO: 1 (human); SEQ ID NO: 2 (mouse)). SEMA4D is expressed as a homodimer on the cell surface, but after cell activation, SEMA4D can be released from the cell surface by proteolytic cleavage to generate a soluble form of the protein, sSEMA4D, which is also biologically active. See Suzuki et al., Nature Rev. Immunol. 3: 159-167 (2003); Kikutani et al., Nature Immunol. 9: 17-23 (2008).
[0005] SEMA4D is expressed at high levels in lymphoid organs including spleen, thymus and lymph nodes and in non-lymphoid organs such as brain, heart and kidney. In lymphoid organs, SEMA4D is expressed in large quantities on resting T cells, but only weakly expressed on resting B cells and antigen presenting cells (APCs) such as dendritic cells (DCs). However, after activation with various immune stimuli, its expression is upregulated in these cells. Cell activation also increases the release of soluble SEMA4D from immune cells. SEMA4D has been closely associated with the development of certain cancers (Ch'ng et al., Cancer 110:164-72 (2007); Campos et al., Oncology Letters, 5:1527-35 (2013); Kato et al., Cancer Sci. 102:2029-37 (2011)) and several reports suggest that one mechanism of this effect is the role of SEMA4D in promoting tumor angiogenesis (Conrotto et al., Blood 105:4321-4329 (2005). Basile et al., J Biol. Chem. 282:34888-34895 (2007); Sierra et al., J. Exp. Med. 205:1673 (2008); Zhou et al., Angiogenesis 15:391-407 (2012)). Tumor growth and metastasis involve interactions between tumor cells, tumor stroma, and immune infiltration, as well as endothelial cells and ducts. SEMA4D is overexpressed in multiple tumor types and is also produced by inflammatory cells recruited to the tumor microenvironment, and the question of what role SEMA4D plays in the migration, survival, differentiation, and organization of the different cell types that make up the tumor stroma remains to be answered. Summary of the invention
[0006] The present invention addresses the need for safe and effective cancer treatments that can be used as a single agent to inhibit, reduce, suppress, prevent, slow or delay the development of tumor cells, shrink tumor cells or directly attack tumor cells, or act in combination with other immunomodulatory treatments to enhance their therapeutic benefits. Specifically, SEMA4D was shown to play a role in the infiltration, maturation and organization of immune cells and macrophages that promote or inhibit tumor growth, which may help develop effective methods for reducing tumor growth and metastasis in subjects with cancer.
[0007] Certain aspects of this application relate to a method of inhibiting, delaying or reducing tumor growth or metastasis or tumor growth and metastasis in a subject suffering from cancer, the method comprising administering to the subject an effective amount of an isolated binding molecule and an effective amount of at least one other immunomodulatory therapy, wherein the binding molecule specifically binds to brain semaphorin-4D (SEMA4D).
[0008] In some embodiments, the binding molecule inhibits the interaction of SEMA4D with its receptor (e.g., plexin-B1). In some embodiments, the binding molecule inhibits SEMA4D-mediated plexin-B1 signal transduction. In some embodiments, the inhibition, delay or reduction of metastasis occurs independently of the primary tumor growth inhibition, delay or reduction. In some embodiments, the cancer is selected from cancer, lymphoma, blastoma, sarcoma, leukemia, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, esophageal cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancer and combinations thereof. In some embodiments, the subject has elevated levels of B cells, T cells, or both B cells and T cells when compared to other subjects with cancer.
[0009] In some embodiments, the isolated binding molecule specifically binds to the same SEMA4D epitope as a reference monoclonal antibody selected from VX15 / 2503 and 67. In some embodiments, the isolated binding molecule comprises an antibody or an antigen binding fragment thereof. In some embodiments, the antibody or its antigen binding fragment comprises 6 complementary determining regions (CDRs) of monoclonal antibody VX15 / 2503 or 67.
[0010] In some embodiments, the immunomodulatory therapy is selected from cancer vaccines, immunostimulants, adoptive T cell or antibody therapy, immune checkpoint blockade, and combinations thereof. In some embodiments, the immunomodulator is selected from the group consisting of interleukins, cytokines, chemokines, antagonists of immune checkpoint blockade, and combinations thereof. In some embodiments, the immunomodulatory therapy may be a cancer therapy. In some embodiments, the cancer therapy is selected from surgery or surgical procedures, radiotherapy, chemotherapy, or a combination thereof. In some embodiments, the separated binding molecule and the immunomodulator or immunomodulatory therapy are administered separately or simultaneously.
[0011] In some embodiments, a method of inhibiting, delaying or reducing tumor growth in a subject with cancer is provided, the method comprising administering to the subject an effective amount of an isolated binding molecule that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment. In some embodiments, the binding molecule inhibits the interaction of SEMA4D with its receptor. In some embodiments, the receptor is plexin-B1. In some embodiments, the binding molecule inhibits SEMA4D-mediated plexin-B1 signal transduction. In some embodiments, the cancer is selected from carcinoma, lymphoma, blastoma, sarcoma, leukemia, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, esophageal cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancer and combinations thereof. In some embodiments, the isolated binding molecule specifically binds to the same SEMA4D epitope as the reference monoclonal antibody VX15 / 2503 or 67. In some embodiments, the isolated binding molecule competitively inhibits the specific binding of the reference monoclonal antibody VX15 / 2503 or 67 to SEMA4D. In some embodiments, the isolated binding molecule comprises an antibody or an antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof has a variable heavy chain (VH) containing VHCDR 1-3 and a variable light chain (VL) containing VLCDR 1-3, VHCDR 1-3 respectively comprising SEQ ID NO: 6, 7 and 8, and VLCDR 1-3 respectively comprising SEQ ID NO: 14, 15 and 16. In some embodiments, VH and VL respectively comprise SEQ ID NO: 9 and SEQ ID NO: 17 or SEQ ID NO: 10 and SEQ ID NO: 18. In some embodiments, the immunomodulatory therapy is selected from the group consisting of administering a cancer vaccine, administering an immunostimulant, adoptive T cell or antibody therapy, administering an immune checkpoint blockade inhibitor, administering a regulatory T cell (Treg) regulator, and a combination thereof. In some embodiments, the immunomodulatory therapy comprises an immune checkpoint blockade inhibitor. In some embodiments, wherein the immune checkpoint blockade inhibitor is an anti-CTLA4 antibody, an anti-PD-1 antibody, or a combination thereof. In some embodiments, the immunomodulatory therapy comprises administering a cancer vaccine. In some embodiments, the Treg regulator is cyclophosphamide. In some embodiments, the isolated binding molecule and the immunomodulatory therapy are administered separately or simultaneously. In some embodiments, administration of the combination of an isolated binding molecule and an immunomodulatory therapy results in enhanced therapeutic efficacy relative to administration of either the isolated binding molecule or the immunomodulatory therapy alone.In some embodiments, when compared to other cancer subjects, the subject has an elevated level of B cells, T cells, or B cells and T cells. In some embodiments, the level of B cells and / or T cells per microliter of blood of the subject is about 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 times the average number of B cells and / or T cells in the circulation of other cancer patients. In some embodiments, for example, compared to other cancer patients, the level of B cells and / or T cells per microliter of blood of the subject ranges from about 147 to about 588 and about 1173 to about 3910, respectively. In some embodiments, the level of B cells and / or T cells of the subject falls within or is higher than the range of B cells and / or T cells of healthy non-cancer patients. In some embodiments, for example, compared to healthy non-cancer patients, the level of B cells and / or T cells per microliter of blood of the subject ranges from about 225 to about 275 or more and about 1350 to about 1650 or more, respectively.
[0012] In some embodiments, a method for treating a subject with cancer with immunotherapy is provided, the method comprising: (a) determining the number of B cells and / or T cells in a subject with cancer; and (b) administering to the subject an effective amount of a separated binding molecule that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment if the number of B cells and / or T cells of the subject exceeds a predetermined threshold level. In some embodiments, the predetermined threshold level of B cells and / or T cells per microliter of blood of the subject is about 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 times the average number of B cells and / or T cells in the circulation of other cancer patients. In some embodiments, for example, the predetermined threshold level of B cells and / or T cells per microliter of blood of the subject ranges from about 147 to about 588 and about 1173 to about 3910, respectively, compared to other cancer patients. In some embodiments, the predetermined threshold level of B cells and / or T cells per microliter of blood in the subject falls within or is higher than the range of B cells and / or T cells in healthy non-cancer patients. In some embodiments, for example, the predetermined threshold levels of B cells and / or T cells per microliter of blood of the subject range from about 225 to about 275 or more and about 1350 to about 1650 or more, respectively, compared to a healthy non-cancer patient.
[0013] In some embodiments, there is provided a method for treating a subject with cancer with immunotherapy, the method comprising: administering to a subject with cancer an effective amount of a combination of a separated binding molecule specifically binding to semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory therapy, wherein the combination is administered to produce a therapeutic efficacy enhanced relative to the administration of the separated binding molecule or other immunomodulatory therapy alone. In some embodiments, immunomodulatory therapy is selected from administering a cancer vaccine, administering an immunostimulant, adoptive T cell or antibody therapy, administering an immune checkpoint blockade inhibitor, administering a regulatory T cell (Treg) regulator, and a combination thereof. In some embodiments, immunomodulatory therapy includes an immune checkpoint blockade inhibitor. In some embodiments, the immune checkpoint blockade inhibitor is an anti-CTLA4 antibody, an anti-PD-1 antibody, or a combination thereof. In some embodiments, immunomodulatory therapy includes administering a cancer vaccine. In some embodiments, the Treg regulator is cyclophosphamide. In some embodiments, the separated binding molecule and immunomodulatory therapy are administered separately or simultaneously. In some embodiments, when compared to other cancer subjects, the subject has an elevated level of B cells, T cells, or B cells and T cells. In some embodiments, the level of B cells and / or T cells per microliter of blood of the subject is about 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 times the average number of B cells and / or T cells circulating in other cancer patients. In some embodiments, for example, the level of B cells and / or T cells per microliter of blood of the subject ranges from about 147 to about 588 and about 1173 to about 3910, respectively, compared to other cancer patients. In some embodiments, the level of B cells and / or T cells of the subject falls within or is higher than the range of B cells and / or T cells of healthy non-cancer patients. In some embodiments, for example, the level of B cells and / or T cells per microliter of blood of the subject ranges from about 225 to about 275 or more and about 1350 to about 1650 or more, respectively, compared to healthy non-cancer patients. In some embodiments, the cancer is selected from carcinoma, lymphoma, blastoma, sarcoma, leukemia, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, esophageal cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancer and combinations thereof. In some embodiments of any of the foregoing methods, the isolated binding molecule specifically binds to the same SEMA4D epitope that is bound to a reference monoclonal antibody selected from VX15 / 2503 or 67. In some embodiments of any of the foregoing methods, the isolated binding molecule competitively inhibits the specific binding of a reference monoclonal antibody selected from VX15 / 2503 or 67 to SEMA4D.In some embodiments, the isolated binding molecule comprises an antibody or an antigen binding fragment thereof. In some embodiments, the antibody or its antigen binding fragment comprises six complementary determining regions (CDRs) of monoclonal antibody VX15 / 2503 or 67. In some embodiments, the antibody or its antigen binding fragment is monoclonal antibody VX15 / 2503 or 67.
[0014] Also provided is a method of inhibiting, delaying or reducing the growth of tumor cells expressing Her2 and plexin B1, plexin B2 or a combination thereof, comprising contacting the tumor cells with an effective amount of an isolated binding molecule that specifically binds to semaphorin-4D (SEMA4D), wherein the growth of the tumor cells is inhibited, delayed or reduced. In some embodiments, the contacting comprises administering a SEMA4D binding molecule to a subject having cancer, wherein the subject's cancer cells express Her2 and plexin B1, plexin B2 or a combination thereof. In some embodiments, the cancer is breast cancer, ovarian cancer, lung cancer or prostate cancer.
[0015] Also provided is a method of treating a subject having cancer, the method comprising: (a) testing the subject for cancer cell expression of Her2 and plexin B1, plexin B2, or a combination thereof; and (b) administering to the subject an effective amount of an isolated molecule that specifically binds to semaphorin-4D (SEMA4D) if the subject's cancer cell expresses Her2 and plexin B1, plexin B2, or a combination thereof. The method of claim 48 or claim 49, the method further comprising administering an effective amount of an anti-HER2 / neu binding molecule. The method of claim 48 or claim 49, wherein the isolated binding molecule specifically binds to the same SEMA4D epitope as the reference monoclonal antibody VX15 / 2503 or 67. The method of claim 48 or claim 49, wherein the isolated binding molecule inhibits the specific binding of the reference monoclonal antibody VX15 / 2503 or 67 to SEMA4D. The method of claim 48 or claim 49, the isolated binding molecule comprises an antibody or an antigen binding fragment thereof. The method of claim 53, wherein the antibody or antigen-binding fragment thereof has a variable heavy chain (VH) comprising VHCDRs 1-3 and a variable light chain (VL) comprising VLCDRs 1-3, wherein VHCDRs 1-3 comprise SEQ ID NOs: 6, 7, and 8, respectively, and VLCDRs 1-3 comprise SEQ ID NOs: 14, 15, and 16, respectively. The method of claim 54, wherein VH and VL comprise SEQ ID NOs: 9 and 17, or SEQ ID NOs: 10 and 18, respectively. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1A-1B: Tumor volume was measured in mice implanted with syngeneic Colon 26 tumor cells. Figure 1A Shown are Colon 26 tumor volumes measured in Balb / c and SCID mice treated twice weekly with 1 mg (50 mg / kg) of anti-SEMA4D antibody (Ab) 67 or 2B8 isotype control immunoglobulin (2B8 Control Ig). Figure 1B Shown are the survival times of Balb / c and SCID mice treated with anti-SEMA4D Ab 67 or 2B8 control Ig as defined in Example 1 below.
[0018] Figure 2 : shows tumor cells implanted and first treated with anti-CD8 depleting antibody (clone 2.43, BioXCell) or control rat Ig (150 mg / kg) and then as Figure 1A Measurement of Colon 26 tumor volume in Balb / c mice treated with 2B8 control Ig or anti-SEMA4D Ab 67 as shown.
[0019] Figure 3A-3B : Measurement of immune cell density in colon 26 tumors transplanted into mice. Figure 3A CD8+ T cell density determined by % of tumor area stained with anti-CD28 antibody after treatment with control Ig or anti-SEMA4D Ab 67 is shown. Figure 3B CD20+ B cell density determined by % of tumor area stained with anti-CD20 antibody after treatment with control Ig or anti-SEMA4D Ab 67 is shown.
[0020] Figures 4A-4D : Measurement of macrophage and CD8+ T cell distribution at the tumor leading edge in Colon 26-engrafted mice. Figure 4A Shown are images of representative colon 26 tumors from mice transplanted 27 days earlier and treated with control Ig or anti-SEMA4D Ab 67 as described in FIG1 . Figure 4B Shown are measurements of M1 macrophage density at the tumor leading edge as determined by the % of pixel area stained with anti-F4 / 80 antibody, with the leading edge defined as a 300 pixel wide region (250 microns) from the tumor edge. Figure 4C Shown are measurements of M2 macrophage density at the tumor leading edge as determined by the % of pixel area stained with anti-CD206 antibody. Figure 4D Shown are measurements of CD8+ T cell density at the tumor leading edge as determined by the % of pixel area stained with cytotoxic T cell anti-CD8 antibodies.
[0021] Figures 5A-5D : Tumor volume measurements in mice implanted with syngeneic Colon 26 tumor cells. Figure 5AShown are colon 26 tumor volume measurements in Balb / c mice treated with IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week), with or without anti-CTLA4 / MAb UC10-4F10-11 (100 μg on day 8 and 50 μg on days 11 and 14 after tumor inoculation), and with anti-PD1 / RMP1-14 (100 μg on day 3, twice a week) in combination with anti-CTLA4 / MAb UC10-4F10-11. Figure 5B Shown are the survival times of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2, with or without anti-CTLA4 / MAb UC10-4F10-11, and with anti-PD1 / RMP1-14 (100 μg on day 3, twice a week) combined with CTLA4 / MAb UC10-4F10-11. Figure 5C Shown are the frequencies of tumor regressions in Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2, with or without anti-CTLA4 / MAb UC10-4F10-11, and with anti-PD1 / RMP1-14 (100 μg on day 3, twice weekly) combined with CTLA4 / MAb UC10-4F10-11. Figure 5D Shown are measurements of the pro-inflammatory cytokine IFNγ in tumor infiltrating lymphocytes of mice treated with a combination of anti-SEMA4D / MAb 67-2 and anti-CTLA4 / MAb UC10-4F10-11 compared to control mice IgG1 / 2B8 or single treatment (anti-SEMA4D / MAb 67-2 or anti-CTLA4 / MAb UC10-4F10-11). Figure 5E Shown are the frequencies of peptide-specific IFNγ secretory responses among tumor-infiltrating lymphocytes recovered from the spleens of mice treated with a combination of anti-SEMA4D / MAb 67-2 and anti-CTLA4 / MAb UC10-4F10-11 compared to control mouse IgG1 / 2B8 or single treatment (anti-SEMA4D / MAb 67-2 or anti-CTLA4 / MAb UC10-4F10-11).
[0022] Figures 6A-6E : Anti-SEMA4D antibodies affect measurement of tumor infiltration of tumor-specific cytotoxic CD8+ T cells. Fig. 6A Shown are measurements of IFNγ-secreting cells from MAb 67-treated mice in the presence or absence of the peptide. Figure 6B Representative ELISPOT images are shown. Figure 6CShows the measurement of anti-tumor cytokines such as IFNγ and TNFα in tumor infiltrating lymphocytes (TILs). Fig.6D Shown is the measurement of pro-inflammatory cytokines IFNγ and TNFα in TILs of mice treated with anti-SEMA4D / MAb 67 antibody. Fig. 6E Shown are the frequencies of peptide-specific IFNγ secretory responses in tumor-infiltrating lymphocytes of mice treated with anti-SEMA4D / MAb 67 antibody.
[0023] Figures 7A-7D : Tumor volume measurements in mice implanted with syngeneic Colon 26 tumor cells. Fig. 7A Shown are Colon 26 tumor volume measurements of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week) and control rat Ig or rat anti-PD1 / MAb RMP1-14 (100 μg, twice a week for 2 weeks starting 3 days after tumor inoculation). Figure 7B Shown are the survival times of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 together with control rat Ig or rat anti-PD1 / MAb RMP1-14. Figure 7C and 7D Shown are the frequencies of tumor regressions in Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 together with control rat Ig or rat anti-PD1 / MAb RMP1-14.
[0024] Figures 8A-8E : Tumor volume measurements in mice implanted with syngeneic Colon 26 tumor cells. Fig. 8A Shown are mean measurements of Colon 26 tumor volume in Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week), with or without cyclophosphamide (CY) (50 mg / kg, ip). Figure 8B Shown are median measurements of Colon 26 tumor volume in Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week), with or without cyclophosphamide (CY) (50 mg / kg, ip). Figure 8C Shown are the survival times of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2, with or without cyclophosphamide. Fig.8D and 8EShown are the frequencies of tumor regressions in Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2, with or without cyclophosphamide (CY).
[0025] Figures 9A-9C : Tumor volume measurements in mice implanted with Tubo.A5 tumor cells. Fig.9A The results show that mice treated with control IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week), with or without anti-Neu / MAb 7.16.4 (αNeu) (200 μg ip twice a week, from tumors with a TV of approximately 200 mm 3 Initially, tumor volume was measured in Balb / c mice treated on days 21 and 28. Fig. 9B Shown are the survival times of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb67-2, with or without anti-Neu / MAb7.16.4 (αNeu). Fig. 9C Shown are the frequencies of tumor regressions in Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2, with or without anti-Neu / MAb 7.16.4 (αNeu).
[0026] Figures 10A-10E : Tumor volume measurements in Balb / c mice implanted with Tubo.A5 tumor cells. Fig. 10A Shown are tumor volume measurements in Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week). Fig. 10B Shown are the survival times of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2. Figures 10C-10E The frequency of tumor regression in the Tubo.A5 tumor model is shown. Specifically, Fig. 10C Control mice implanted with Tubo.A5 tumors are shown. Fig. 10D Shown are mice that had eliminated Tubo.A5 tumor xenografts following treatment with anti-SEMA4D / MAb 67-2 and were re-challenged with Tubo.A5 tumors at day 90 after the original transplantation. Fig.10E Display with Fig. 10D Naive mice were challenged with the same tumor xenografts to demonstrate tumor viability in vivo.
[0027] Figures 11A-11B : Measurement of T cell infiltration and MDSCs in the Tubo.A5 tumor model. Fig.11AShown are measurements of CD3+ T cells in tumors of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week). Fig. 11B Shown are measurements of CD11b+Grl+MDSCs in tumors of Balb / c mice treated with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, once a week).
[0028] Figures 12A-12D : Tumor volume measurements in mice implanted with Colon 26 or Tubo.A5 tumor cells. Fig. 12A Shown are Tubo.A5 tumor volume measurements in Balb / c mice treated with control mouse IgG1 / 2B8.1E7 (50 mg / kg, ip, 6 times per week) or varying levels of anti-SEMA4D / MAb 67-2 (1, 10 or 50 mg / kg, ip, 6 times per week). Fig. 12B Shown are the survival times of Balb / c mice treated with control mouse IgG1 / 2B8.1E7 (50 mg / kg, ip, 6 times per week) or varying levels of anti-SEMA4D / MAb67-2 (1, 10 or 50 mg / kg, ip, 6 times per week). Fig. 12C Shown are measurements of Colon 26 tumor cells in Balb / c mice treated with control mouse IgG1 / 2B8.IE7 (50 mg / kg, ip, 5 times per week), anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, 5 times per week), anti-CTLA4 / MAb UC10-4F10-11 (5 mg / kg, ip, 5 times per week), or a combination of anti-CTLA4 / MAb UC10-4F10-11 (5 mg / kg, ip, 5 times per week) and varying levels of anti-SEMA4D / MAb 67-2 (0.3, 3, 10 or 50 mg / kg, ip, 5 times per week). Fig.12D Shown are the survival times of Balb / c mice treated with control mouse IgG1 / 2B8.IE7 (50 mg / kg, ip, 5 times per week), anti-SEMA4D / MAb 67-2 (50 mg / kg, ip, 5 times per week), anti-CTLA4 / MAb UC10-4F10-11 (5 mg / kg, ip, 5 times per week), or a combination of anti-CTLA4 / MAb UC10-4F10-11 (5 mg / kg, ip, 5 times per week) and varying levels of anti-SEMA4D / MAb 67-2 (0.3, 3, 10 or 50 mg / kg, ip, 5 times per week).
[0029] Fig.13 : Summary of experiments performed in the above figures showing tumor regression and growth following tumor re-challenge in the Colon 26 and Tubo.A5 tumor models. DETAILED DESCRIPTION OF THE INVENTION
[0031] I. Definitions
[0032] It should be noted that the term "a" or "an" substance refers to one or more of the substance; for example, "a polynucleotide" should be understood to represent one or more polynucleotides. Therefore, the terms "a" (or "a"), "one or more" and "at least one" can be used interchangeably herein.
[0033] In addition, the use of "and / or" herein should be considered to specifically disclose each of the two features or components, with or without the other. Therefore, the term "and / or" used in the phrase "A and / or B" herein tends to include "A and B", "A or B", "A" (alone), and "B" (alone). Similarly, the term "and / or" used in phrases such as "A, B, and / or C" tends to include various following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd edition, 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd edition, 1999, Academic Press; and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide a common dictionary of many terms used in the present invention to the skilled person.
[0035] Units, prefixes and symbols are expressed in the form accepted by their International System of Units (SI). Numerical ranges include numerical values that limit the range. Unless otherwise stated, amino acids are written from left to right with an amino to carboxyl orientation. The titles provided herein are not limitations of the various aspects or embodiments of the present invention, and the various aspects or embodiments of the present invention can be understood with reference to the specification as a whole. Therefore, the terms defined immediately below are fully defined with reference to the full text of the specification.
[0036] In any embodiment described with the language "comprising," other similar embodiments of "consisting of" and / or "consisting essentially of are also provided.
[0037] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Similarly, nucleotides are referred to by their commonly accepted single-letter codes.
[0038] As used herein, the terms "cancer" and "carcinoma" refer to or describe a physiological condition in a mammal in which a cell population is characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias. More specific examples of such cancers include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, esophageal cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, and various types of head and neck cancer.
[0039] In certain embodiments, metastatic cancers suitable for treatment by the methods provided herein include, but are not limited to, metastatic sarcomas, breast cancer, ovarian cancer, head and neck cancer, and pancreatic cancer. In certain embodiments, metastatic cancers or tumor cells suitable for treatment by the methods provided herein express the plexin-B1 and / or plexin-B2 receptors of SEMA4D.
[0040] "Angiogenesis" refers to the complex multi-step morphogenetic events during which endothelial cells, stimulated by the major determinants of vascular remodeling, dynamically modify their cell-cell and cell-matrix contacts and move in a directional manner to reorganize into a mature vascular tree (Bussolino et al., Trends Biochem Sci. 22: 251-256 (1997); Risau, Nature 386: 671-674 (1997); Jain, Nat. Med. 9: 685-693 (2003)). The formation of new blood vessels is a key step during embryonic development, but it also occurs in physiological and pathological conditions in adults, such as retinopathy, rheumatoid arthritis, ischemia, and especially in tumor growth and metastasis (Carmeliet, Nat. Med. 9: 653-660 (2003)).
[0041] As used herein, the term "clinical laboratory" refers to a facility that examines or processes materials from living subjects, such as humans. Non-limiting examples of processing include biological, biochemical, serological, chemical, immunohematological, hematological, physiological, cytological, pathological, genetic, or other examinations of materials from the human body for purposes such as providing information on the diagnosis, prevention, or treatment of any disease or injury in a living subject, such as a human, or the evaluation or health of a subject, such as a human. These examinations may include the process of collecting or obtaining samples, preparing, determining, measuring, or describing the presence or absence of various substances in a sample in or obtained from a living subject, such as a human body.
[0042] The terms "proliferative disease" and "proliferative disorder" refer to diseases associated with abnormal cell proliferation, such as cancer.
[0043] As used herein, "tumor" and "neoplasm" refer to any tissue mass resulting from excessive cell growth or proliferation, benign (noncancerous) or malignant (cancerous), including precancerous lesions. In certain embodiments, the tumors described herein express plexin-B1 and / or plexin-B2, and may express SEMA4D and activated Met.
[0044] As used herein, the term "health care benefit provider" includes an individual department, organization, or group that, in whole or in part, provides, donates, supplies, pays for, or is associated with providing access to one or more health care benefits, benefit plans, health insurance, and / or medical expense account plans for patients.
[0045] The term "immunomodulatory therapy" or "immunotherapy" refers to a treatment that affects a disease or condition in a subject by inducing and / or strengthening an immune response in the subject. Immunomodulatory therapy includes cancer vaccines, immunostimulants, adoptive T cell or antibody therapy, and immune checkpoint blockade (Lizée et al., 2013. Harnessing the Power of the Immune System to Target Cancer. Annu. Rev. Med. Vol. 64 Nos. 71-90).
[0046] The term "immunomodulator" refers to an active agent for immunotherapy. Immunomodulators include different arrays of recombinant, synthetic and natural preparations. Examples of immunomodulators include, but are not limited to, interleukins such as IL-2, IL-7, IL-12; cytokines such as granulocyte colony stimulating factor (G-CSF), interferon; various chemokines such as CXCL13, CCL26, CXCL7; antagonists of immune checkpoint blockade, such as anti-CTLA-4, anti-PD1 or anti-PD-L1 (ligand of PD-1), anti-LAG3, anti-B7-H3, synthetic cytosine phosphate-guanine (CpG) oligodeoxynucleotides, dextran; and regulators of regulatory T cells (Treg) such as cyclophosphamide.
[0047] As used herein, the terms "metastasis", "metastatic cancer", "metastatic" or other grammatical synonyms refer to cancer cells that spread or metastasize from an initially unknown (e.g., primary tumor) or other area of the body and develop similar cancerous lesions at the new location. "Metastatic" or "positively metastatic" cells are cells that lose adhesive contacts with adjacent cells and migrate from the primary site of the disease through the bloodstream or lymph to invade adjacent body structures. The term also refers to the process of metastasis, which includes but is not limited to the shedding of cancer cells from cancer cells of the primary tumor, the entry of cancer cells into blood vessels into the circulation, their survival and migration to different sites, adhesion and extravasation from the circulation to new sites, and micro-colonization at different sites, and tumor growth and development at different sites.
[0048] The term "therapeutically effective amount" refers to an amount of an antibody, polypeptide, polynucleotide, small organic molecule or other drug that is effective for "treating" a disease or condition in a subject or mammal. In the case of cancer, a therapeutically effective amount of a drug can reduce the number of cancer cells; block or stop cancer cell division, reduce or block the increase in tumor size; inhibit, for example, suppress, block, prevent, stop, delay or reverse cancer cell infiltration to peripheral organs, including, for example, cancer spread to soft tissue and bone; inhibit, for example, suppress, block, prevent, shrink, stop, delay or reverse tumor metastasis; inhibit, for example, suppress, block, prevent, stop, delay or reverse tumor growth; alleviate one or more symptoms associated with cancer to some extent, reduce morbidity and mortality; improve quality of life; or a combination of these effects. To the extent that a drug prevents growth and / or kills existing cancer cells, it can be referred to as cell growth inhibition and / or cytotoxicity.
[0049] Terms such as "treat" or "alleviate" refer to both 1) curing, slowing, reducing symptoms of, reversing and / or stopping the progression of a diagnosed pathological condition or disease and 2) preventive measures to prevent and / or slow the development of a targeted pathological condition or disease. Thus, those in need of treatment include those already suffering from the disease; those susceptible to the disease; and those in need of prevention of the disease. A subject is successfully "treated" according to the methods of the present invention if the patient exhibits one or more of the following conditions: a decrease in the number of cancer cells or a complete disappearance of cancer cells; a decrease in tumor size; or a retardation or reversal of tumor growth, inhibition, e.g., suppression, prevention, retardation, shrinkage, delay or reversal of metastasis, such as cancer cell infiltration into peripheral organs, including, e.g., spread of cancer cells into soft tissue and bone; inhibition, e.g., suppression, retardation, prevention, shrinkage, reversal, delay, or disappearance of tumor metastasis; inhibition, e.g., suppression, retardation, prevention, shrinkage, reversal, delay, or disappearance of tumor growth; alleviation of one or more symptoms associated with a particular tumor; reduction in morbidity and mortality; improvement in quality of life; or some combination of effects. Beneficial or desired clinical results include, but are not limited to, detectable or undetectable relief of symptoms, reduction in disease extent, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or alleviation of the disease state, and remission (partial or complete). "Treatment" may also refer to prolonging survival compared to the expected survival without treatment. Those in need of treatment include those already suffering from a condition or disease, as well as those prone to a condition or disease or those in need of prevention of a condition or disease.
[0050] "Subject" or "individual" or "animal" or "patient" or "mammal" refers to any subject in need of diagnosis, prevention or treatment, especially a mammalian subject. Mammalian subjects include humans, domestic animals, livestock and zoo animals, competitive animals or pets, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, bears, etc.
[0051] As used herein, terms such as "a subject who would benefit from administration of an anti-SEMA4D antibody as a single agent or in combination with at least one other immunomodulatory therapy" and "an animal in need of treatment" include subjects, such as mammalian subjects, who would benefit from administration of an anti-SEMA4D antibody as a single agent or in combination with at least one other immunomodulatory therapy.
[0052] In a broad sense, the "binding molecules" or "antigen binding molecules" of the present invention refer to molecules that specifically bind to antigenic determinants. In one embodiment, the binding molecule specifically binds to SEMA4D, for example, a transmembrane SEMA4D polypeptide of about 150 kDa or a soluble SEMA4D polypeptide of about 120 kDa (commonly referred to as sSEMA4D). In another embodiment, the binding molecule of the present invention is an antibody or an antigen binding fragment thereof. In another embodiment, the binding molecule of the present invention includes at least one heavy chain or light chain complementary determining region (CDR) of an antibody molecule. In another embodiment, the binding molecule of the present invention includes at least 2 CDRs from one or more antibody molecules. In another embodiment, the binding molecule of the present invention includes at least 3 CDRs from one or more antibody molecules. In another embodiment, the binding molecule of the present invention includes at least 4 CDRs from one or more antibody molecules. In another embodiment, the binding molecule of the present invention includes at least 5 CDRs from one or more antibody molecules. In another embodiment, the binding molecule of the present invention includes at least 6 CDRs from one or more antibody molecules. In another embodiment, the binding molecule can be an antagonist of the plexin-B1 receptor of SEMA4D. Antagonists represent binding molecules that interfere with the signal transduction function of receptors. Antagonists competitively block the binding of natural ligands but fail to trigger normal physiological responses. The binding molecule may be an antibody or antigen-binding fragment thereof as described herein, or may be other biological agents or small molecule drugs that act as competitive inhibitors or interfere with the signal transduction of natural ligands. The present invention relates to methods for inhibiting tumor growth and metastasis in subjects, such as cancer patients, comprising administering to the subject an anti-SEMA4D binding molecule, such as an antibody, or an antigen-binding fragment, variant or derivative thereof, as a single agent or in combination with at least one other immunomodulatory treatment. Unless specifically mentioned are full-sized antibodies such as naturally occurring antibodies, the term "anti-SEMA4D antibody" includes full-sized antibodies and antigen-binding fragments, variants, analogs or derivatives of such antibodies, such as naturally occurring antibodies or immunoglobulin molecules, or engineered antibody molecules or fragments that bind to antigens in a manner similar to antibody molecules. Other biological agents or small molecules that bind to and inhibit the activity of SEMA4D or its plexin-B1 receptor are also included in SEMA4D binding molecules.
[0053] As used herein, "human" or "fully human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from a human immunoglobulin library or one or more human immunoglobulin transgenic animals, as described below, for example, in U.S. Pat. No. 5,939,598 to Kucherlapati et al. "Human" or "fully human" antibodies also include antibodies comprising at least a heavy chain variable region or at least a heavy chain and a light chain variable region, wherein the variable region has the amino acid sequence of a human immunoglobulin variable region.
[0054] "Human" or "fully human" antibodies also include "human" or "fully human" antibodies as described above that comprise, consist essentially of, or consist of variants (including derivatives) of antibody molecules described herein (such as VH regions and / or VL regions), which antibodies or fragments thereof immunologically specifically bind to a SEMA4D polypeptide or a fragment or variant thereof. Mutations can be introduced into the nucleotide sequence encoding a human anti-SEMA4D antibody using standard techniques known to those skilled in the art, including, but not limited to, site-directed mutagenesis and PCR-mediated mutagenesis that cause amino acid substitutions. In certain aspects, the variant (including derivatives) encodes less than 50 amino acid substitutions, less than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to a reference VH region, VHCDR1, VHCDR2, VHCDR3, VL region, VLCDR1, VLCDR2, or VLCDR3.
[0055] In certain embodiments, the amino acid substitution is a conservative amino acid substitution, as described in detail below. Alternatively, mutations can be introduced randomly along all or a portion of the coding sequence, such as by saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity (e.g., the ability to bind to a SEMA4D polypeptide, such as human SEMA4D, mouse SEMA4D, or both human and mouse SEMA4D). Such variants of "human" or "fully human" antibodies (or derivatives thereof) can also be referred to as "optimized" or "antigen-binding optimized" human or fully human antibodies, including antibodies with improved affinity for the antigen.
[0056] The terms "antibody" and "immunoglobulin" are used interchangeably herein. An antibody or immunoglobulin comprises at least a heavy chain variable region, and typically comprises at least a heavy chain and a light chain variable region. Basic immunoglobulin structures in vertebrate systems are well understood. See, e.g., Harlow et al. (1988) Antibodies: A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press).
[0057] The term "immunoglobulin" as used herein includes various types of polypeptides that can be distinguished biochemically. It will be understood by those skilled in the art that heavy chains are divided into gamma, muon, alpha, delta or epsilon (γ, μ, α, δ, ε), among which there are also some subclasses (such as γ1-γ4). The characteristics of the chain determine that the antibody "class" is IgG, IgM, IgA, IgG or IgE, respectively. Immunoglobulin subclasses (isotypes) such as IgG1, IgG2, IgG3, IgG4, IgA1, etc. have been well characterized and are known to confer functional specialization. According to the disclosure herein, it is not difficult for those skilled in the art to distinguish modified forms of these classes and isotypes, and therefore, they are covered within the scope of the present invention. All immunoglobulin classes obviously belong to the scope of the present invention, and the following discussion is generally directed to the IgG class of immunoglobulin molecules. In IgG, a standard immunoglobulin molecule includes two identical light chain polypeptides with a molecular weight of about 23,000 Daltons and two identical heavy chain polypeptides with a molecular weight of 53,000-70,000. The four chains are typically connected by disulfide bonds in a "Y" configuration, with the light chains holding up the heavy chains from the mouth of the Y and continuing through the variable region.
[0058] Light chains are classified as either kappa or lambda. Each heavy chain class can be combined with a kappa or lambda light chain. Typically, the light and heavy chains are covalently bound to each other, and when immunoglobulins are produced by hybridomas, B cells, or genetically engineered host cells, the "tail" portions of the two heavy chains are bound together by covalent disulfide bonds or non-covalent linkages. In the heavy chain, the amino acids are from the N-terminus at the forked end of the Y configuration to the C-terminus at the base of each chain.
[0059] Both the light chain and the heavy chain are divided into regions of structural and functional homology. The terms "constant" and "variable" are used from a functional perspective. In this regard, it should be understood that the variable regions of the light chain (VL or VK) and heavy chain (VH) portions determine antigen recognition and specificity. In contrast, the constant regions of the light chain (CL) and heavy chain (CH1, CH2 or CH3) produce important biological properties, such as secretion, transplacental movement, Fc receptor binding, complement binding, etc. By convention, the numbering of the constant region domains increases as they move away from the antigen binding site or the amino terminus of the antibody. The N-terminal region is a variable gas and the C-terminal region is a constant region; the CH3 and CL domains actually include the carboxyl termini of the heavy and light chains, respectively.
[0060] As described above, the variable region allows the antibody to selectively recognize and specifically bind to an epitope on an antigen. That is, the VL and VH domains of the antibody, or the complementary determining regions (CDR) subgroups within these variable regions, combine to form a variable region that determines a three-dimensional antigen binding site. This tetravalent antibody structure forms an antigen binding site present at the end of each arm of the Y. More specifically, the antigen binding site is determined by three CDRs on each VH and VL chain. In some cases, such as in certain immunoglobulin molecules derived from alpaca species or engineered according to alpaca immunoglobulins, a complete immunoglobulin molecule may consist only of heavy chains without light chains. See, for example, Hamers-Casterman et al., Nature 363:446-448 (1993).
[0061] In naturally occurring antibodies, the six "complementarity determining regions" or "CDRs" present on each antigen binding domain are short, non-contiguous amino acid sequences that are specifically positioned to form the antigen binding domain as the antibody determines its three-dimensional configuration in an aqueous environment. The remaining amino acids in the antigen binding domain are called "framework" regions and show less intermolecular differences. The framework regions primarily adopt a β-sheet conformation, and the CDRs form loops that connect and in some cases form part of the β-sheet structure. Thus, the framework regions serve to form a scaffold that provides the CDRs with the correct orientation through interchain non-covalent interactions. The antigen binding domain formed by the positioned CDRs defines a surface that is complementary to an epitope on an immunoreactive antigen. This complementary surface promotes non-covalent binding of the antibody to its complementary epitope. For any given heavy or light chain variable region, one of ordinary skill in the art can readily identify the amino acids comprising the CDRs and framework regions, respectively, because they have been precisely defined (see below).
[0062] Unless expressly stated to the contrary, where a term has two or more definitions used and / or accepted in the art, the definition of the term used herein shall include all of these meanings. A specific example is the use of the term "complementarity determining region" ("CDR") to describe the non-contiguous antigen binding sites found within the variable regions of heavy and light chain polypeptides. This particular region is described in Kabat et al. (1983) U.S. Department of Health and Human Services, "Sequences of Proteins of Immunological Interest" and Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987) (the above documents are incorporated herein by reference in their entirety), and the definitions include overlapping amino acid residues or amino acid residue subsets when compared to each other. Nevertheless, the use of any definition to refer to a CDR of an antibody or variant thereof shall fall within the scope of the term as defined and used herein. Suitable amino acid residues include the CDRs defined in the references cited above, which are listed in Table 1 below for comparison. The exact residue numbering that comprises a particular CDR varies depending on the sequence and size of the CDR. Given the variable region amino acid sequence of an antibody, one skilled in the art can routinely determine which residues comprise a particular CDR.
[0063] Table 1. CDR definitions 1
[0064]
[0065]
[0066] 1 The numbering of all CDR definitions in Table 1 follows the numbering convention described by Kabat et al. (see below).
[0067] Kabat et al. also defined a numbering system applicable to the variable region sequence of any antibody. One of ordinary skill in the art can clearly apply the "Kabat numbering" system to any variable region sequence without relying on any experimental data outside the sequence itself. The "Kabat numbering" used herein refers to the numbering system described in Kabat et al. (1983), U.S. Department of Health and Human Services, "Sequences of Proteins of Immunological Interest". Unless otherwise indicated, when referring to the numbering of specific amino acid residue positions in the anti-SEMA4D antibodies of the present invention or their antigen-binding fragments, variants or derivatives, the Kabat numbering system is used.
[0068] The antibodies or antigen-binding fragments, variants, or derivatives thereof of the present invention include, but are not limited to, polyclonal, monoclonal, multispecific, bispecific, human, humanized, primatized or chimeric antibodies, single-chain antibodies, epitope-binding fragments such as Fab, Fab' and F(ab')2, Fd, Fv, single-chain Fv (scFv), disulfide-linked Fv (sdFv), fragments comprising VL or VH domains, fragments produced by Fab expression libraries, and anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies of the anti-SEMA4D antibodies described herein). ScFv molecules are known in the art and are described, for example, in U.S. Pat. No. 5,892,019. The immunoglobulin or antibody molecules of the present invention can be any type (such as IgG, IgE, IgM, IgD, IgA and IgY), class (such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2, etc.) or subclass of immunoglobulin molecules.
[0069] The term "heavy chain portion" as used herein includes an amino acid sequence derived from an immunoglobulin heavy chain. In certain embodiments, the polypeptide comprises a heavy chain portion comprising at least one of the following: a VH domain, a CH1 domain, a hinge (e.g., an upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, the binding polypeptide used in the present invention may include a polypeptide chain containing a CH1 domain; a polypeptide chain containing a CH1 domain, at least a portion of a hinge region, and a CH2 domain; a polypeptide chain containing a CH1 domain and a CH3 domain; a polypeptide chain containing a CH1 domain, at least a portion of a hinge region, and a CH3 domain, or a polypeptide chain containing a CH1 domain, at least a portion of a hinge region, a CH2 domain, and a CH3 domain. In another embodiment, the polypeptide of the present invention includes a polypeptide chain containing a CH3 domain. In addition, the binding polypeptide used in the present invention may lack at least a portion of a CH2 domain (e.g., all or part of a CH2 domain). As noted above, those of ordinary skill in the art will appreciate that these domains (eg, heavy chain portions) can be modified so that their amino acid sequence differs from that of a naturally occurring immunoglobulin molecule.
[0070] In certain anti-SEMA4D antibodies disclosed herein, or antigen-binding fragments, variants or derivatives thereof, the heavy chain portion of one polypeptide chain of the multimer is identical to the second polypeptide chain of the multimer. Alternatively, the monomers containing the heavy chain portion of the present invention are different. For example, each monomer may contain a different target binding site, forming, for example, a bispecific antibody. A bispecific antibody is an artificial protein composed of fragments of two different monoclonal antibodies and thus binds to two different types of antigens. Variations in the form of bispecific antibodies are contemplated within the scope of the present invention. For example, bispecific antibodies can be generated using techniques well known in the art, see, e.g., Ghayur et al., Expert Review of Clinical Pharmacology 3.4 (July 2010): p. 491; Lu et al., J. Biological Chemistry Vol. 280, No. 20, pp. 19665-19672 (2005); Marvin et al., Acta Pharmacologic Sinica 26(6): 649-658 (2005); and Milstein C et al., Nature 1983; 305: 537-40; 30 Brennan M et al., Science 1985; 229: 81-3; Thakur et al., Curr Opin Mol Ther. Jun. 2010; 12(3): 340-9; and U.S. Patent Publication No. 2007 / 0004909.
[0071] The heavy chain portion of the binding molecule used in the methods described herein can be derived from different immunoglobulin molecules. For example, the heavy chain portion of the polypeptide can include a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another example, the heavy chain portion can include a hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG3 molecule. In another example, the heavy chain portion can include a chimeric hinge that is partially derived from an IgG1 molecule and partially derived from an IgG4 molecule.
[0072] As used herein, the term "light chain portion" includes an amino acid sequence derived from an immunoglobulin light chain, such as a kappa or lambda light chain. In certain aspects, the light chain portion comprises at least one of a VL or CL domain.
[0073] The anti-SEMA4D antibodies described herein, or antigen-binding fragments, variants or derivatives thereof, may be described or illustrated based on the antigens they recognize or specifically bind to, such as epitopes or portions of target polypeptides (such as SEMA4D) described herein. The portion of the target polypeptide that specifically interacts with the antigen-binding domain of the antibody is an "epitope" or "antigenic determinant". The target polypeptide may contain a single epitope, but typically contains at least two epitopes, and may include any number of epitopes, depending on the size, conformation and type of the antigen. Moreover, it should be noted that an "epitope" on a target polypeptide may be or may include a non-polypeptide element, for example, an epitope may include a sugar side chain.
[0074] It is believed that the minimum size of a peptide or polypeptide epitope of an antibody is about 4 to 5 amino acids. A peptide or polypeptide epitope may contain at least 7, at least 9, and in some cases at least about 15 to about 30 amino acids. Since CDRs can recognize antigenic peptides or polypeptides in a tripartite form, the amino acids comprising the epitope are not necessarily contiguous and may not even be on the same peptide chain in some cases. The peptide or polypeptide epitope recognized by the anti-SEMA4D antibody of the present invention may contain at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, or about 15-about 30 contiguous or non-contiguous amino acids in SEMA4D.
[0075] "Specific binding" generally refers to that the antibody binds to the epitope through its antigen binding domain, and the binding requires a certain degree of complementarity between the antigen binding domain and the epitope. According to this definition, when the antibody binds to the epitope through its antigen binding domain more easily than to a random, unrelated epitope, the antibody is said to "specifically bind" to the epitope. The term "specificity" is used herein to qualitatively analyze the relative affinity of a certain antibody binding to a certain epitope. For example, antibody "A" can be considered to have a higher specificity or affinity for a given epitope than antibody "B", or antibody "A" is said to bind to epitope "C" with a higher specificity or affinity than the specificity or affinity of the related epitope "D".
[0076] "Preferentially binds" means that the antibody specifically binds to an epitope more readily than to a related, similar, homologous, or analogous epitope. Thus, an antibody that "preferentially binds" a given epitope is more likely to bind to that epitope than to a related epitope, even though the antibody may cross-react with the related epitope.
[0077] As a non-limiting example, if the dissociation constant (K) of an antibody binding to a first epitope is D ) is lower than the K of the antibody and the second epitope D , then the antibody can be considered to preferentially bind to the first epitope. In another non-limiting example, if the antibody binds to the first epitope with a higher affinity than the antibody to the second epitope, DIn another non-limiting example, an antibody may be considered to preferentially bind to a first antigen if the antibody has a K affinity for the first epitope that is at least one order of magnitude lower than the K affinity for the second epitope. D If the binding affinity of the antibody is at least 2 orders of magnitude lower, then the antibody can be considered to preferentially bind to the first epitope.
[0078] In another non-limiting example, an antibody may be considered to preferentially bind to a first epitope if the antibody binds to the first epitope with a lower off rate (k(off)) than the antibody's k(off) for the second epitope. In another non-limiting example, an antibody may be considered to preferentially bind to a first epitope if the antibody binds to the first epitope with an affinity that is at least 1 order of magnitude lower than the antibody's k(off) for the second epitope. In another non-limiting example, an antibody may be considered to preferentially bind to a first epitope if the antibody binds to the first epitope with an affinity that is at least 2 orders of magnitude lower than the antibody's k(off) for the second epitope.
[0079] If an antibody preferentially binds to a given epitope to such an extent that it blocks binding of a reference antibody to that epitope, then the antibody is said to competitively inhibit binding of a reference antibody to that epitope. Competitive inhibition can be determined by any method known in the art, e.g., a competition ELISA assay. It can be said that the antibody competitively inhibits binding of a reference antibody to a given epitope by at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%.
[0080] The term "affinity" as used herein refers to a measure of the strength of binding of an individual epitope to a CDR of an immunoglobulin molecule. See, for example, Harlow et al. (1988) Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 2nd ed.), pp. 27-28. The term "avidity" as used herein refers to the overall stability of the complex between an immunoglobulin population and an antigen, i.e., the functional binding strength of an immunoglobulin mixture to an antigen. See, for example, Harlow, pp. 29-34. Avidity is related both to the affinity of individual immunoglobulin molecules in the population to a specific epitope and to the valence of the immunoglobulin molecules to the antigen. For example, the interaction between a bivalent monoclonal antibody and an antigen having a highly repetitive epitope structure, such as a polymer, is an example of high affinity.
[0081] The anti-SEMA4D antibodies or antigen-binding fragments, variants or derivatives thereof of the present invention may also be described or illustrated in terms of their cross-reactivity. The term "cross-reactivity" as used herein refers to the ability of an antibody to react with a second antigen with specificity for one antigen; it is a measure of the association between two different antigenic substances. Thus, an antibody is cross-reactive if it binds to an epitope other than the epitope that induced its formation. Cross-reactive epitopes typically contain many of the same complementary structural features as the induced epitope, and in some cases are even more closely matched than the original epitope.
[0082] For example, certain antibodies have a certain degree of cross-reactivity because they bind to related but not identical epitopes, e.g., epitopes that are at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identical to a reference epitope (calculated as known in the art and described herein). An antibody can be said to have low or no cross-reactivity if it does not bind to an epitope that is less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identical to a reference epitope (calculated as known in the art and described herein). An antibody can be said to be "highly specific" for an epitope if it does not bind to any other analog, ortholog, or homolog of an epitope.
[0083] The anti-SEMA4D binding molecules of the invention, such as antibodies or antigen-binding fragments, variants or derivatives thereof, can be described or specified based on their binding affinity to a polypeptide of the invention, such as SEMA4D, such as human, mouse, or human and mouse SEMA4D. In certain aspects, the binding affinity includes a dissociation constant or Kd of less than 5x10 -2 M, 10 -2 M, 5x10 -3 M, 10 -3 M, 5x10 -4 M, 10 -4 M, 5x10 -5 M, 10 -5 M, 5x10 -6 M, 10 -6 M, 5x10 -7 M, 10 -7 M, 5x10 -8 M, 10 -8 M, 5x10 -9 M, 10 -9 M, 5x10 -10 M, 10 -10 M, 5x10 -11 M, 10-11 M, 5x10 -12 M, 10 -12 M, 5x10 -13 M, 10 -13 M, 5x10 -14 M, 10 -14 M, 5x10 -15 M or 10 -15 In certain embodiments, the anti-SEMA4D binding molecules, e.g., antibodies or antigen-binding fragments thereof of the invention are present in an amount of about 5×10 -9 About 6x10 -9 In another embodiment, the anti-SEMA4D binding molecule, e.g., an antibody or antigen-binding fragment thereof of the invention, binds to human SEMA4D with a Kd of about 1×10 -9 About 2x10 -9 Kd for binding to murine SEMA4D.
[0084] The term "chimeric antibody" as used herein refers to any antibody in which the immunoreactive region or site is obtained or derived from a first species, while the constant region (which may be complete, partial or modified) is obtained from a second species. In some embodiments, the target binding region or site will be from a non-human source (e.g., mouse or primate) and the constant region is human.
[0085] The term "engineered antibody" as used herein refers to an antibody that changes the variable region in the heavy chain or light chain or both by at least partially replacing one or more CDRs from an antibody with known specificity and, if necessary, by partial framework region replacement and sequence changes. Although CDRs can be derived from antibodies belonging to the same class or even subclass as the antibody that produces the framework region, it is envisioned that CDRs are derived from antibodies of different classes or antibodies of different species. The engineered antibodies formed by transplanting one or more "donor" CDRs from non-human antibodies with known specificity into human heavy or light chain framework regions are referred to herein as "humanized antibodies". In certain aspects, it may not be necessary to replace all CDRs with complete CDRs from donor variable regions to transfer the antigen binding capacity of one variable region to another variable region. Instead, only residues necessary for maintaining binding site activity for the target antigen can be transferred.
[0086] It is further recognized that the framework regions within the variable domains in the heavy chain or light chain or both of the humanized antibodies may contain only residues of human origin, in which case these framework regions of the humanized antibodies are referred to as "complete human framework regions" (e.g., MAb VX15 / 2503, MAb 2503 in U.S. Patent Application Publication No. US2010 / 0285036 A1, the entire text of which is incorporated herein by reference). Alternatively, if it is necessary to maintain appropriate binding to the SEMA4D antigen or to improve binding, one or more residues of the framework region in the donor variable region may be engineered within the corresponding positions of the human framework region in the heavy chain or light chain or both variable regions of the humanized antibody. Therefore, the human framework region engineered in this manner comprises a mixture of human and donor framework region residues, referred to herein as a "partial human framework region."
[0087] For example, the humanization of anti-SEMA4D antibodies can be performed essentially as described by Winter and coworkers (Jones et al., Nature 321: 522-525 (1986); Riechmann et al., Nature 332: 323-327 (1988); Verhoeyen et al., Science 239: 1534-1536 (1988)), i.e., rodent or mutant rodent CDRs or CDR sequences are substituted for the corresponding sequences of human anti-SEMA4D antibodies. See also U.S. Pat. Nos. 5,225,539; 5,585,089; 5,693,761; 5,693,762; 5,859,205; which are incorporated herein by reference. The resulting humanized anti-SEMA4D antibody will contain at least one rodent or mutant rodent CDR within the complete human framework region of the heavy and / or light chain variable region of the humanized antibody. In some cases, residues within the framework region of one or more variable regions of a humanized anti-SEMA4D antibody are replaced by corresponding non-human (e.g., rodent) residues (see, e.g., U.S. Pat. Nos. 5,585,089; 5,693,761; 5,693,762; and 6,180,370), in which case the resulting humanized anti-SEMA4D antibody will contain a partial human framework region within the variable region of the heavy chain and / or light chain. Similar methods can be used for humanization of anti-VEGF antibodies.
[0088] Furthermore, humanized antibodies may include residues that are not found in the recipient antibody or the donor antibody. These modifications are made to further improve antibody performance (e.g., to obtain desired affinity). Typically, a humanized antibody will comprise substantially all of at least one, usually two, variable regions, in which all or substantially all of the CDRs correspond to those of a non-human immunoglobulin, and all or substantially all of the framework regions are framework regions of human immunoglobulin sequences. The humanized antibody may also optionally comprise at least a portion of an immunoglobulin constant region (Fc), generally that of a human immunoglobulin. For further details, see Jones et al., Nature, 331: 522-525 (1986); Riechmann et al., Nature, 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992); which are incorporated herein by reference in their entirety. Thus, the "humanized" antibody may include antibodies in which significantly less than the complete human variable region is replaced by the corresponding sequence from a non-human species. In practice, humanized antibodies are generally human antibodies in which some CDR residues and possibly some framework residues are replaced by residues from similar sites in rodent antibodies. See, e.g., U.S. Patent Nos. 5,225,539; 5,585,089; 5,693,761; 5,693,762; 5,859,205. See also U.S. Patent No. 6,180,370 and International Publication No. WO 01 / 27160, which disclose humanized antibodies and techniques for producing humanized antibodies with improved affinity for a predetermined antigen.
[0089] II. Target peptide description - SEMA4D
[0090] As used herein, the terms "semaphorin-4D", "SEMA4D" and "SEMA4D polypeptide" are used interchangeably, such as "SEMA4D" and "Sema4D". In certain embodiments, SEMA4D is expressed on the surface of a cell or secreted by a cell. In another embodiment, SEMA4D is membrane-bound. In another embodiment, SEMA4D is soluble, such as sSEMA4D. In another embodiment, SEMA4D may include full-size SEMA4D or a fragment thereof, or a SEMA4D variant polypeptide, wherein the fragment of SEMA4D or a SEMA4D variant polypeptide retains some or all of the functional properties of the full-size SEMA4D.
[0091] The full-size human SEMA4D protein is a homodimeric transmembrane protein composed of two 150 kDa polypeptide chains. SEMA4D belongs to the semaphorin family of cell surface receptors and is also known as CD100. Human and mouse SEMA4D / Sema4D are proteolytically cleaved from their transmembrane forms to form a 120-kDa soluble form, resulting in two Sema4D isoforms (Kumanogoh et al., J. Cell Science 116(7):3464 (2003)). Semaphorins consist of soluble and membrane-bound proteins that were originally defined as axon guidance factors that play an important role in establishing precise connections between neurons and their appropriate targets. Structurally, the class IV semaphorin, SEMA4D, consists of an amino-terminal signal sequence followed by a characteristic "Sema" domain, which contains 17 conserved cysteine residues, an Ig-like domain, a lysine-rich extension, a hydrophobic transmembrane domain, and a cytoplasmic tail.
[0092] The SEMA4D polypeptide comprises a signal sequence of about 13 amino acids, followed by a semaphorin domain of about 512 amino acids, an immunoglobulin-like (Ig-like) domain of about 65 amino acids, a lysine-rich extension of 104 amino acids, a hydrophobic transmembrane region of about 19 amino acids, and a cytoplasmic tail of 110 amino acids. The consensus site of tyrosine phosphorylation in the cytoplasmic tail supports the predicted binding of SEMA4D to tyrosine kinases (Schlossman et al., eds., (1995) Leucocyte Typing V (Oxford, Oxford University Press, Oxford)).
[0093] SEMA4D is known to have at least three functional receptors, plexin-B1, plexin-B2, and CD72. Plexin-B1 is expressed in non-lymphoid tissues and has been shown to be a high affinity (1 nM) receptor for SEMA4D (Tamagnone et al., Cell 99: 71-80 (1999)). SEMA4D stimulation of plexin B1 signaling has been shown to induce growth cone collapse of neurons, and process extension collapse and apoptosis of oligodendrocytes (Giraudon et al., J. Immunol. 172: 1246-1255 (2004); Giraudon et al., NeuroMolecular Med. 7: 207-216 (2005)). After binding to SEMA4D, plexin B1 signaling mediates the inactivation of R-Ras, resulting in a decrease in integrin-mediated extracellular matrix adhesion, and the activation of RhoA, resulting in cell collapse by reorganizing the cytoskeleton. See Kruger et al., Nature Rev. Mol. Cell Biol. 6:789-800 (2005); Pasterkamp, TRENDS in Cell Biology 15:61-64 (2005). Plexin-B2 has a moderate affinity for SEMA4D, and recent reports indicate that PLXNB2 is expressed on keratinocytes and activates SEMA4D-positive γδ T cells to promote epithelial repair (Witherden et al., Immunity. 2012 Aug 24; 37(2):314-25).
[0094] In lymphoid tissues, CD72 acts as a low-affinity (300 nM) SEMA4D receptor (Kumanogoh et al., Immunity 13: 621-631 (2000)). B cells and antigen presenting cells (APCs) express CD72, and anti-CD72 antibodies have many of the same effects as sSEMA4D, such as enhancing CD40-induced B cell responses and B cell shedding of CD23. CD72 is thought to act as a negative regulator of B cell responses by recruiting the casein phosphatase SHP-1, which can associate with many inhibitory receptors. The interaction of SEMA4D with CD72 results in the dissociation of SHP-1 and the loss of this negative activation signal. SEMA4D has been shown to promote T cell stimulation and B cell aggregation and survival in vitro. Addition of SEMA4D-expressing cells or sSEMA4D enhances CD40-induced B cell proliferation and immunoglobulin production in vitro and accelerates antibody responses in vivo (Ishida et al., Inter. Immunol. 15: 1027-1034 (2003); Kumanogoh and H. Kukutani, Trends in Immunol. 22: 670-676 (2001)). sSEMA4D enhances CD40-induced DC maturation, including upregulation of co-stimulatory molecules and increased IL-12 secretion. In addition, sSEMA4D can inhibit immune cell migration, which can be reversed by adding blocking anti-SEMA4D mouse antibodies (Elhabazi et al., J. Immunol. 166: 4341-4347 (2001); Delaire et al., J. Immunol. 166: 4348-4354 (2001)).
[0095] Sema4D is expressed at high levels in lymphoid organs including the spleen, thymus and lymph nodes, as well as in non-lymphoid organs such as the brain, heart and kidneys. In lymphoid organs, Sema4D is abundantly expressed on resting T cells, but only weakly expressed on resting B cells and antigen presenting cells (APCs) such as dendritic cells (DCs).
[0096] Cellular activation increases the surface expression of SEMA4D and the production of soluble SEMA4D (sSEMA4D). The expression characteristics of SEMA4D suggest that it plays an important physiological and pathological role in the immune system. SEMA4D has been shown to promote B cell activation, aggregation and survival; enhance CD40-induced proliferation and antibody production; enhance antibody responses to T cell antigens; increase T cell proliferation; enhance dendritic cell maturation and the ability to stimulate T cells; and is directly involved in demyelination and axonal degeneration (Shi et al., Immunity 13: 633-642 (2000); Kumanogoh et al., J Immunol 169: 1175-1181 (2002); and Watanabe et al., J Immunol 167: 4321-4328 (2001)).
[0097] SEMA4D knockout (SEMA4D- / -) mice have provided additional evidence that SEMA4D plays an important role in humoral and cellular immune responses. There are no known non-lymphoid tissue abnormalities in SEMA4D- / - mice. Dendritic cells (DCs) from SEMA4D- / - mice have poor stimulatory capacity and show defects in the expression of co-stimulatory molecules, which can be rescued by the addition of sSEMA4D. SEMA4D-deficient (SEMA4D- / -) mice are unable to develop experimental autoimmune myelitis induced by myelin oligodendrocyte glycoprotein peptide because myelin oligodendrocyte glycoprotein-specific T cells are weakly generated in the absence of SEMA4D (Kumanogoh et al., J Immunol 169: 1175-1181 (2002)). Significant amounts of soluble SEMA4D were also detected in the serum of autoimmune-prone MRL / lpr mice (a model of systemic autoimmune diseases such as SLE) but not in normal mice. In addition, the level of sSEMA4D correlates with the level of autoantibodies and increases with age (Wang et al., Blood 97: 3498-3504 (2001)). Soluble SEMA4D has also been shown to accumulate in the cerebrospinal fluid and serum of patients with demyelinating diseases, and sSEMA4D induces apoptosis of human multipotent neural precursors (Dev cells), and simultaneously inhibits process expansion and induces apoptosis of rat oligodendrocytes in vitro (Giraudon et al., J Immunol 172 (2): 1246-1255 (2004)). This apoptosis is blocked by anti-SEMA4D monoclonal antibodies (MAbs).
[0098] III. Anti-SEMA4D Antibodies
[0099] Antibodies that bind to SEMA4D have been described in the art. See, for example, U.S. Publication Nos. 2008 / 0219971A1, US 2010 / 0285036 A1, and US 2006 / 0233793 A1, International Patent Applications WO 93 / 14125, WO 2008 / 100995, and WO 2010 / 129917, and Herold et al., Int. Immunol. 7(1): 1-8 (1995), each of which is incorporated herein by reference in its entirety.
[0100] The present invention generally relates to a method for inhibiting, delaying or reducing tumor growth or metastasis in a subject, such as a human cancer patient, comprising administering an antibody, or an antigen binding fragment, variant or derivative thereof that specifically binds to SEMA4D. In certain embodiments, the antibody blocks the interaction of SEMA4D with one or more of its receptors, such as plexin-B1 and / or plexin-B2. In certain embodiments, cancer cells express plexin-B1 and / or plexin-B2. Anti-SEMA4D antibodies with these properties can be used in the methods provided herein. Useful antibodies include, but are not limited to MAbs VX15 / 2503, 67, 76, 2282 and their antigen binding fragments, variants or derivatives, all of which are described in US 2010 / 0285036 A1 and US 2008 / 0219971 A1. Other antibodies that can be used in the methods provided herein include the BD16 antibody described in US 2006 / 0233793 A1, and antigen-binding fragments, variants, or derivatives thereof; or any of MAb 301, MAb 1893, MAb 657, MAb 1807, MAb 1656, MAb 1808, Mab 59, MAb 2191, MAb 2274, MAb 2275, MAb 2276, MAb 2277, MAb 2278, MAb 2279, MAb 2280, MAb 2281, MAb 2282, MAb 2283, MAb 2284, and MAb 2285, and any fragments, variants, or derivatives thereof, as described in US 2008 / 0219971 A1. In certain embodiments, the anti-SEMA4D antibodies used in the methods provided herein bind to human, murine, or both human and murine SEMA4D.Antibodies that bind to the same epitope as any of the foregoing antibodies and / or antibodies that competitively inhibit the binding or activity of any of the foregoing antibodies can also be used.
[0101] In certain embodiments, the anti-SEMA4D antibodies or antigen-binding fragments, variants or derivatives thereof useful in the methods provided herein have an amino acid sequence having at least about 80%, about 85%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94% or about 95% sequence identity with the amino acid sequence of a reference anti-SEMA4D antibody molecule, e.g., those described above. In another embodiment, the binding molecule shares at least about 96%, about 97%, about 98%, about 99% or 100% sequence identity with the reference antibody.
[0102] In another embodiment, an anti-SEMA4D antibody or antigen-binding fragment, variant or derivative thereof that can be used in the methods provided herein comprises, consists essentially of or consists of an immunoglobulin heavy chain variable region (VH domain), wherein at least one CDR of the VH domain has an amino acid sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% identical or completely identical to CDR1, CDR2 or CDR3 of SEQ ID NO: 9, 10, 25 or 48.
[0103] In another embodiment, an anti-SEMA4D antibody or antigen-binding fragment, variant or derivative thereof that can be used in the methods provided herein comprises, consists essentially of, or consists of an immunoglobulin heavy chain variable region (VH domain), wherein at least one CDR of the VH domain has an amino acid sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% identical or completely identical to SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 27 or SEQ ID NO: 28.
[0104] In another embodiment, the anti-SEMA4D antibody or antigen-binding fragment, variant or derivative thereof that can be used in the methods provided by the present invention comprises, consists essentially of or consists of an immunoglobulin heavy chain variable region (VH domain), wherein at least one CDR of the VH domain has an amino acid sequence that is exactly the same as SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 27 or SEQ ID NO: 28, except for 1, 2, 3, 4 or 5 conservative amino acid substitutions.
[0105] In another embodiment, an anti-SEMA4D antibody, or antigen-binding fragment, variant, or derivative thereof, useful in the methods provided herein comprises, consists essentially of, or consists of a VH domain having an amino acid sequence that is at least about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identical to SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 25, or SEQ ID NO: 48, wherein the anti-SEMA4D antibody comprises an encoded VH domain that specifically or preferentially binds SEMA4D.
[0106] In another embodiment, the anti-SEMA4D antibody or antigen-binding fragment, variant or derivative thereof that can be used in the methods provided by the present invention comprises, consists essentially of or consists of an immunoglobulin light chain variable region (VL domain), wherein at least one CDR of the VL domain has an amino acid sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% identical or completely identical to CDR1, CDR2 or CDR3 of SEQ ID NO: 17, 18, 29 or 47.
[0107] In another embodiment, an anti-SEMA4D antibody or antigen-binding fragment, variant or derivative thereof that can be used in the methods provided herein comprises, consists essentially of, or consists of an immunoglobulin light chain variable region (VL domain), wherein at least one CDR of the VL domain has an amino acid sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% identical or completely identical to SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32.
[0108] In another embodiment, the anti-SEMA4D antibody or antigen-binding fragment, variant or derivative thereof that can be used in the methods provided by the present invention comprises, consists essentially of or consists of an immunoglobulin light chain variable region (VL domain), wherein at least one CDR of the VL domain has an amino acid sequence that is exactly the same as SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32, except for 1, 2, 3, 4 or 5 conservative amino acid substitutions.
[0109] In another embodiment, an anti-SEMA4D antibody, or antigen-binding fragment, variant, or derivative thereof, useful in the methods provided herein comprises, consists essentially of, or consists of a VL domain having an amino acid sequence that is at least about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identical to SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 29, or SEQ ID NO: 47, wherein the anti-SEMA4D antibody comprises an encoded VL domain that specifically or preferentially binds SEMA4D.
[0110] Also used in the methods provided herein are polypeptides encoding the anti-SEMA4D antibodies described herein, or antigen-binding fragments, variants or derivatives thereof, polynucleotides encoding such polypeptides, vectors comprising such polynucleotides, and host cells comprising such vectors or polynucleotides, all for producing anti-SEMA4D antibodies, or antigen-binding fragments, variants or derivatives thereof for use in the methods described herein.
[0111] Suitable biologically active variants of the anti-SEMA4D antibodies of the invention can be used in the methods of the invention. Such variants will retain the desired binding properties of the parent anti-SEMA4D antibody. Methods for preparing antibody variants are generally available in the art.
[0112] Methods for mutagenesis and alteration of nucleotide sequences are well known in the art. See, e.g., Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York); Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492 (1985); Kunkel et al., Methods Enzymol. 154:367-382 (1987); Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, NY); U.S. Pat. No. 4,873,192; and references cited therein; which are incorporated herein by reference. Guidance for suitable amino acid substitutions that do not affect the biological activity of the polypeptide of interest can be found in the model in Dayhoff et al. (1978), Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, DC), pp. 345-352, which is incorporated herein by reference in its entirety. The model of Dayhoff et al. utilizes a Point Accepted Mutation (PAM) amino acid similarity matrix (PAM 250 matrix) to determine suitable conservative amino acid substitutions. In certain aspects, conservative substitutions are used, such as replacing one amino acid with another amino acid having similar properties. Examples of conservative amino acid substitutions taught in the PAM 250 matrix of Dayhoff et al.'s model include, but are not limited to: and
[0113] When constructing variants of the anti-SEMA4D binding molecules, such as antibodies or antigen-binding fragments thereof, polypeptides of interest, modifications are generated so that the variants continue to possess the desired properties, such as the ability to specifically bind to SEMA4D, such as human, primate, mouse, or human and mouse SEMA4D, for example, expressed on the surface or secreted by cells, and having SEMA4D blocking activity, as described herein. In certain aspects, mutations in the DNA encoding the variant polypeptides maintain the reading frame and do not generate complementary regions that may produce secondary mRNA structure. See European Patent Application Publication No. 75,444.
[0114] Methods for determining the binding specificity of an anti-SEMA4D binding molecule, such as an antibody or an antigen-binding fragment, variant or derivative thereof include, but are not limited to, standard competitive binding assays, T cell or B cell immunoglobulin secretion monitoring assays, T cell proliferation assays, apoptosis assays, ELISA assays, etc. See, for example, WO 93 / 14125; Shi et al., Immunity 13:633-642 (2000); Kumanogoh et al., J Immunol 169:1175-1181 (2002); Watanabe et al., J Immunol 167:4321-4328 (2001); Wang et al., Blood 97:3498-3504 (2001); and Giraudon et al., J Immunol 172 (2):1246-1255 (2004), all of which are incorporated herein by reference.
[0115] Methods for measuring the anti-angiogenic ability of an anti-SEMA4D antibody or antigen-binding fragment, variant or derivative thereof are well known in the art.
[0116] When discussing herein whether any particular polypeptide disclosed herein (including a constant region, CDR, VH domain, or VL domain) is at least about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or even about 100% identical to another polypeptide, the percent identity can be determined using methods and computer programs / software known in the art, such as, but not limited to, the BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Avenue, Madison, WI 53711). 53711). BESTFIT uses the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2: 482-489 to find the best homology segment between two sequences. When using BESTFIT or any other sequence alignment program to determine whether a particular sequence is (for example) 95% identical to a reference sequence described in the present invention, the parameters are of course set so that the percent identity is calculated over the entire length of the reference polypeptide sequence and up to 5% homology gaps are allowed in the total number of amino acids in the reference sequence.
[0117] For purposes of the present invention, the Smith-Waterman homology search algorithm can be used to determine the percent sequence identity, which uses an affine gap search with a gap opening penalty of 12 points, a gap extension penalty of 2 points, and a BLOSUM matrix score of 62 points. The Smith-Waterman homology search algorithm is disclosed in Smith and Waterman (1981) Adv. Appl. Math. 2: 482-489. The variant can differ from the reference anti-CXCL13 antibody (e.g., MAb VX15 / 2503, 67, 76 or 2282) by, for example, as few as 1-15 amino acid residues, as few as 1-10 amino acid residues, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.
[0118] The constant region of an anti-SEMA4D antibody can be mutated in a variety of ways to alter effector function. For example, see U.S. Pat. No. 6,737,056 Bl and U.S. Patent Application Publication No. 2004 / 0132101 Al, which disclose Fc mutations that optimize antibody binding to Fc receptors.
[0119] In the anti-SEMA4D antibodies or fragments, variants or derivatives thereof that can be used in the methods provided herein, the Fc portion can be mutated using techniques known in the art to reduce effector function. For example, the deletion or inactivation of the constant region domain (by point mutation or other means) can reduce the binding of the circulating modified antibody to the Fc receptor, thereby improving tumor localization. In other cases, constant region modifications consistent with the present invention regulate complementary binding and thus shorten serum half-life. Other modifications of the constant region can be used to change the disulfide bond connection or oligosaccharide portion, which can enhance localization due to increased antigen specificity or antibody flexibility. Without too much experimentation, the physiological profile, bioavailability and other biochemical effects produced by the modification, such as tumor localization, biodistribution and serum half-life, can be easily determined or quantitatively analyzed using well-known immunological techniques.
[0120] Anti-SEMA4D antibodies for use in the methods provided herein include modified derivatives, such as by covalently attaching any type of molecule to the antibody, such that the covalent attachment does not prevent the antibody from specifically binding to its cognate epitope. For example, but not limited to, antibody derivatives include antibodies modified by methods such as glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivatization by known protection / blocking groups, proteolytic cleavage, attachment to cellular ligands or other proteins, and the like. Any of a variety of chemical modifications can be performed by known techniques, including but not limited to: specific chemical cleavage, acetylation, formylation, and the like. In addition, the derivatives may contain one or more non-classical amino acids.
[0121] "Conservative amino acid substitution" is the substitution of an amino acid residue by an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art. These families include: amino acids with basic side chains (such as lysine, arginine, histidine), amino acids with acidic side chains (such as aspartic acid, glutamic acid), amino acids with uncharged polar side chains (such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with non-polar side chains (such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with β-branched side chains (such as threonine, valine, isoleucine) and amino acids with aromatic side chains (such as tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity (e.g., the ability to bind an anti-SEMA4D polypeptide to block the interaction of SEMA4D with its receptor, or inhibit, delay or reduce metastasis in a subject, such as a cancer patient).
[0122] For example, mutations may be introduced only in the framework region of the antibody molecule or only in the CDR region. The mutations introduced may be silent or natural missense mutations, i.e., there is no or little effect on the ability of the antibody to bind antigens. These mutation types can be used to optimize codon usage, or to improve the antibody production of hybridomas. Alternatively, non-natural missense mutations can change the ability of the antibody to bind antigens. Those skilled in the art will be able to design and test mutant molecules with desired properties, such as no antigen binding activity or changes in binding activity (e.g., improving antigen binding activity or changing antibody specificity). After mutagenesis, the encoded protein can be conventionally expressed and can use the technology described herein or by conventional modification techniques known in the art to determine the function and / or biological activity of the encoded protein (e.g., the ability of at least one epitope of the immunospecific binding SEMA4D polypeptide).
[0123] In certain embodiments, the anti-SEMA4D antibodies used in the methods provided herein comprise at least one optimized complementarity determining region (CDR). An "optimized CDR" refers to a CDR that has been modified and optimized to improve the binding affinity and / or anti-SEMA4D activity of an anti-SEMA4D antibody comprising an optimized CDR. "Anti-SEMA4D activity" or "SEMA4D blocking activity" may include activities that modulate one or more of the following activities associated with SEMA4D: B cell activity, aggregation and survival; CD40-induced proliferation and antibody production; antibody response to T cell-dependent antigens; T cell or other immune cell proliferation; dendritic cell maturation; demyelination and axonal degeneration; apoptosis of multipotent neural precursors and / or oligodendrocytes; induction of endothelial cell migration; inhibition of spontaneous monocyte migration; inhibition, delay or reduction of tumor cell growth or metastasis, binding to cell surface plexin B1 or other receptors, or any other activity associated with soluble SEMA4D or SEMA4D expressed on the surface of SEMA4D+ cells. In certain embodiments, the anti-SEMA4D activity includes inhibition, delay or reduction of tumor metastasis, in combination with inhibition, delay or reduction of primary tumor cell growth and tumor metastasis, or independent of primary tumor cell growth and tumor metastasis. Anti-SEMA4D activity may also result in a reduction in the incidence or severity of diseases associated with SEMA4D expression, including but not limited to certain types of cancer including lymphoma, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejection and invasive angiogenesis. Examples of optimized antibodies based on mouse anti-SEMA4D MAb BD16 are described in U.S. Patent Publication No. 2008 / 0219971 A1, International Patent Application No. WO 93 / 14125 and Herold et al., Int. Immunol. 7(1): 1-8 (1995), each of which is incorporated herein by reference in its entirety. Modifications may include substitutions of amino acid residues within the CDRs such that the anti-SEMA4D antibody retains specificity for the SEMA4D antigen and has improved binding affinity and / or improved anti-SEMA4D activity.
[0124] IV. Binding properties of anti-SEMA4D antibodies
[0125] In certain embodiments, the binding molecule is an antibody that specifically binds to SEMA4D, or an antigen-binding fragment, variant, or derivative thereof. In certain embodiments, the binding molecule binds to an epitope of SEMA4D. The nucleotide and amino acid sequences of one variant of SEMA4D are shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively, and the nucleotide and amino acid sequences of another variant of SEMA4D are shown in SEQ ID NO: 15 and SEQ ID NO: 16, respectively. In some embodiments, an anti-SEMA4D antibody named VX15 / 2503 is provided. Antibodies having the binding properties of antibody VX15 / 2503 are also disclosed herein. Such antibodies include, but are not limited to, antibodies that compete in a competitive binding assay with VX15 / 2503, and antibodies that bind to an epitope (defined below) that can bind to VX15 / 2503. Methods for evaluating whether antibodies have the same or similar binding properties include traditional quantitative methods, for example, determining and comparing antibody affinity or avidity for an antigenic epitope (e.g., a SEMA4D peptide). Other exemplary methods for comparing the binding properties of antibodies include competitive western blotting, enzyme immunoassay, ELISA and flow cytometry. Methods for evaluating and comparing antibody-antigen binding properties are well known in the art. Variants and fragments of VX15 / 2503 that retain the ability to specifically bind SEMA4D are also provided. Antibodies VX15 / 2503 and 67 have the same 6 CDRs and bind to the same SEMA4D epitope.
[0126] In some embodiments, the anti-SEMA4D antibodies described herein, or antigen-binding fragments, variants, or derivatives thereof, can be described or illustrated based on the antigens they recognize or specifically bind to, such as an epitope or portion of a target polypeptide (such as SEMA4D) described herein. The portion of a target polypeptide that specifically interacts with the antigen-binding domain of an antibody is an "epitope" or "antigenic determinant."
[0127] In some embodiments, "epitope" is often used to generate antibodies and / or the part of the antigenic molecule that the antibody will specifically bind. "SEMA4D epitope" includes the part of the SEMA4D protein that the anti-SEMA4D antibody binds. The epitope can include linear amino acid residues (i.e., residues in the epitope arranged continuously one after another in a linear manner), non-linear amino acid residues (referred to as "non-linear epitope" or "conformational epitope" in this article; These epitopes are not arranged continuously), or linear and non-linear amino acid residues simultaneously. Non-linear epitopes or conformational epitopes may also include amino acid residues that cause the overall conformation of the recognition structure of the antibody, but they do not have to be combined with antibodies. Typically, an epitope is a short amino acid sequence, for example, with a length of about 5 amino acids. Systematic classification techniques for identifying epitopes are known in the art and are described in, for example, the following embodiments.
[0128] The target polypeptide may contain a single epitope, but typically contains at least two epitopes, and may include any number of epitopes, depending on the size, conformation and type of the antigen. Furthermore, it should be noted that an "epitope" on a target polypeptide may be or may include a non-polypeptide element, for example, an epitope may include a sugar side chain.
[0129] It is believed that the minimum size of a peptide or polypeptide epitope of an antibody is about 4 to 5 amino acids. A peptide or polypeptide epitope may contain at least 7, at least 9, and the latter at least about 15 to about 30 amino acids. Since CDRs can recognize antigenic peptides or polypeptides in a tripartite form, the amino acids comprising the epitope are not necessarily contiguous and may not even be on the same peptide chain in some cases. The peptide or polypeptide epitope recognized by the anti-SEMA4D antibody of the present invention may contain at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, or about 15 to about 30 contiguous or non-contiguous amino acids in SEMA4D.
[0130] In some embodiments, the epitope is at least 80%, 85%, 90%, 95% or 100% identical to a target polypeptide amino acid sequence (e.g., the sequence shown in SEQ ID NO:42, SEQ ID NO:44 or SEQ ID NO:46).
[0131] In some embodiments, the epitope is identical to the target polypeptide amino acid sequence (e.g., the sequence shown in SEQ ID NO: 42, SEQ ID NO: 44, or SEQ ID NO: 46) except for 4, 3, 2, 1, or 0 amino acid substitutions. In another embodiment, the epitope is identical to the target polypeptide amino acid sequence (e.g., the sequence shown in SEQ ID NO: 42, SEQ ID NO: 44, or SEQ ID NO: 46) except for conservative amino acid substitutions (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 conservative amino acid substitutions).
[0132] In some embodiments, the epitope comprises the sequence set forth in SEQ ID NO: 42, SEQ ID NO: 44, or SEQ ID NO: 46. In another embodiment, the epitope is the sequence set forth in SEQ ID NO: 42, SEQ ID NO: 44, or SEQ ID NO: 46. In some embodiments, the epitope is a linear epitope. In some embodiments, the epitope is a conformational epitope.
[0133] In some embodiments, the epitope comprises, consists essentially of, or consists of LKVPVFYALFTPQLNNV (SEQ ID NO: 42, corresponding to residues 304 to 320 of the full-length SEMA4D amino acid sequence set forth in SEQ ID NO: 1), KWTSFLKARLIASRP (SEQ ID NO: 44, corresponding to residues 270 to 284 of the full-length SEMA4D amino acid sequence set forth in SEQ ID NO: 1, wherein position 281 may be cysteine or alanine), or EFVFRVLIPRIARV (SEQ ID NO: 46, corresponding to residues 243 to 256 of the full-length SEMA4D amino acid sequence set forth in SEQ ID NO: 1). In some embodiments, the epitope comprises one or more of the amino acid sequences set forth in SEQ ID NO: 42, 44, and 46. In some embodiments, the epitope is a discontinuous epitope contained in a domain spanning amino acid residues 243 to 320 of SEQ ID NO: 1.
[0134] V. Treatment Methods Using Therapeutic Anti-SEMA4D Antibodies as Single Agents or in Combination with At least One Immunomodulatory Therapy
[0135] The methods of the present invention involve the use of anti-SEMA4D or anti-plexin-B1 binding molecules, e.g., antibodies, including antigen-binding fragments, variants, and derivatives thereof as a single agent or in combination with at least one other immunomodulatory treatment to inhibit, delay, or reduce tumor growth or metastasis in a subject in need of such inhibition, delay, or reduction, such as a cancer patient. In certain embodiments, the cancer cells express a SEMA4D receptor, and in certain embodiments, the receptor is plexin-B1. Although the following description relates to the administration of anti-SEMA4D antibodies, the methods described herein are equally applicable to antigen-binding fragments, variants, and derivatives of these antibodies that retain the desired properties of the antibodies of the present invention, e.g., capable of specifically binding to SEMA4D, e.g., human, mouse, or human and mouse SEMA4D, having SEMA4D neutralizing activity, and / or blocking the interaction of SEMA4D with its receptor. The methods described herein are also applicable to other biological products or small molecule drugs that retain the desired properties of the antibodies of the present invention, e.g., capable of specifically binding to SEMA4D, e.g., human, mouse, or human and mouse SEMA4D, having SEMA4D neutralizing activity, and / or blocking the interaction of SEMA4D with its receptor.
[0136] In one embodiment, anti-SEMA4D molecules, such as antibodies, including antigen-binding fragments, variants and derivatives thereof, can be used as a single agent to inhibit, delay or reduce tumor growth in an object that needs such inhibition, delay or reduction, such as a cancer patient. In certain embodiments, cancer cells express SEMA4D receptors, such as plexin-B1 or plexin-B2. In other embodiments, cancer cells express other receptors that can act in conjunction with the SEMA4D receptor. An example of such a receptor is HER2 (ErbB2). Examples of cancers in which plexin-B1 or plexin-B2 have been observed to be expressed in conjunction with Her2 include lung cancer, breast cancer, prostate cancer and ovarian cancer. Thus, in certain embodiments, anti-SEMA4D molecules, such as antibodies, including antigen-binding fragments, variants and derivatives thereof, can be used as a single agent to inhibit, delay or reduce tumor growth in an object suffering from lung cancer, breast cancer, prostate cancer or ovarian cancer.
[0137] In one embodiment, immunomodulatory therapy includes cancer vaccines, immunostimulants, adoptive T cell or antibody therapy, and inhibitors of immune checkpoint blockade (Lizée et al., 2013. Harnessing the Power of the Immune System to Target Cancer. Annu. Rev. Med. Vol. 64 No. 71-90).
[0138] Cancer vaccines. Cancer vaccines activate the body's immune system and natural resistance to abnormal cells, such as cancer, leading to eradication or control of the disease. Cancer vaccines generally consist of tumor antigens in an immunogenic formulation that activates tumor antigen-specific helper cells and / or CTLs and B cells. Vaccines can be in a variety of formulations, including, but not limited to, dendritic cells, particularly autologous dendritic cells pulsed with tumor cells or tumor antigens, allogeneic tumor cells transfected with an immunostimulant such as GM-CSF, recombinant viruses, or proteins or peptides, usually administered with a potent immunoadjuvant, such as CpG.
[0139] Immunostimulants. Immunostimulants act to enhance or increase the immune response to tumors, which is suppressed in many cancer patients through a variety of mechanisms. Immunomodulatory therapy can target lymphocytes, macrophages, dendritic cells, natural killer cells (NK cells), or subsets of these cells, such as cytotoxic T lymphocytes (CTL) or natural killer T (NKT) cells. Due to the interactive immune cascade, the effect on a group of immune cells will usually be amplified by development to other cells, for example, enhanced antigen presenting cell activity promotes the response of T and B lymphocytes. Examples of immunostimulants include, but are not limited to, HER2, cytokines such as G-CSF, GM-CSF and IL-2, cell membrane fragments from bacteria, glycolipids that bind to CD1d to activate natural killer T (NKT) cells, and CpG oligonucleotides.
[0140] Granulocytes and macrophages of the immune system are a fundamental part of the innate defense mechanism, which can promote specific immunity by inducing T cell recruitment and activation. Despite this, their presence within the tumor microenvironment has been associated with enhanced tumor development and has been shown to promote cancer cell growth and spread, angiogenesis, and immunosuppression. The key to setting their phenotype is the microenvironmental signals that macrophages are exposed to, which selectively regulate their function within a functional spectrum that includes M1 (tumor suppressor macrophages) and M2 (tumor promoting macrophages) extremes. Sica et al., Seminars in Cancer Biol. 18: 349-355 (2008). Increased numbers of macrophages during tumors are associated with poor prognosis (Qualls and Murray, Curr. Topics in Develop. Biol. 94: 309-328 (2011)). Among the many unique somatic cell types commonly found in solid tumors, tumor-associated macrophages (TAMs) are significant for promoting tumor development. Targeted molecular pathways that regulate TAN polarization are promising for anticancer therapy. Ruffell et al., Trends in Immunol. 33: 119-126 (2012).
[0141] Adoptive cell transfer. Adoptive cell transfer can use T cell-based cytotoxic responses to attack cancer cells. Autologous T cells with natural or genetically engineered activity against the patient's cancer are generated and proliferated in vitro and then transferred back to the cancer patient. One study demonstrated that adoptive transfer of autologous tumor-infiltrating lymphocytes proliferated in vitro is an effective treatment for patients with metastatic melanoma. (Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (April 2008). "Adoptive cell transfer: a clinical path to effective cancer immunotherapy". Nat. Rev. Cancer 8 (4): 299-308). This can be achieved by obtaining T cells found in the resected patient tumor. These T cells are transferred to tumor-infiltrating lymphocytes (TIL) and are presumably transported to the tumor due to their specificity for tumor antigens. High concentrations of IL-2, anti-CD3 and alloreactive feeder cells can be used to induce the proliferation of these T cells in vitro. These T cells are then transferred back to the patient along with exogenously administered IL-2 to further enhance their anti-cancer activity. In other studies, autologous T cells have been transduced with chimeric antigen receptors that confer responsiveness to targeted tumor antigens (Liddy et al., Nature Med. 18:980-7, (2012); Grupp et al., New England J. Med. 368:1509-18, (2013)).
[0142] Other adoptive cell transfer therapies employ autologous dendritic cells that are contacted ex vivo with natural or modified tumor antigens, which are then re-infused into the patient. Provenge is an FDA-approved therapy in which autologous cells are incubated with a fusion protein of prostatic acid phosphatase and GM-CSF to treat patients with prostate tumors. GM-CSF is believed to promote the differentiation and activity of antigen-presenting dendritic cells (Small et al., J. Clin. Oncol. 18: 3894-903 (2000); U.S. Pat. No. 7,414,108).
[0143] Immune checkpoint blockade. Immune checkpoint blockade therapy enhances T cell immunity by removing negative feedback controls that limit ongoing immune responses. These types of treatments target inhibitory pathways in the immune system, which are critical for regulating the duration and amplitude of physiological immune responses in peripheral tissues (anti-CTLA4) or tumor tissues expressing PD-L1 (anti-PD1 or anti-PD-L1) to minimize collateral tissue damage. Tumors can evolve to use certain immune checkpoint pathways as the main mechanism of immune tolerance of T cells specific to tumor antigens. Since many immune checkpoints are triggered by ligand-receptor interactions, these checkpoints can be closed by antibodies against receptors or ligands or can be regulated by soluble recombinant forms of ligands or receptors. Neutralization of immune checkpoints allows tumor-specific T cells to continue to play a role in other immunosuppressive tumor microenvironments. Examples of immune checkpoint blockade therapy are those targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), PD-1, its ligands PD-L1, LAG3, and B7-H3.
[0144] Cyclophosphamide. Cyclophosphamide, a commonly used chemotherapy, can enhance the immune response. Cyclophosphamide differentially inhibits the function of regulatory T cells (Tregs) relative to effector T cells. Tregs are important in regulating anti-cancer immune responses. Tumor-infiltrating Tregs have previously been associated with poor prognosis. Although, there are currently no agents that specifically target Tregs, cyclophosphamide has emerged as a clinically feasible agent that can preferentially inhibit Tregs relative to other T cells, and thus allow for a more effective induction of anti-tumor immune responses.
[0145] Other immunomodulatory therapies: In another embodiment, therapy with a SEMA4D or plexin-B1 binding molecule, such as an antibody or an antigen-binding fragment, variant, or derivative thereof, can be combined with low-dose chemotherapy or radiotherapy. Although standard chemotherapy is generally immunosuppressive, low doses of chemotherapeutic agents such as cyclophosphamide, doxorubicin, and paclitaxel have been shown to enhance responses to vaccine treatments against cancer (Machiels et al., Cancer Res. 61: 3689-3697 (2001)). In some cases, chemotherapy can differentially inactivate myeloid-derived suppressor cells (MDSC) and T regulatory cells (Treg) that negatively regulate immune responses in the tumor environment. Radiotherapy has generally been used to exploit the direct tumor-killing effects of ionizing radiation. In fact, high doses of radiation, like chemotherapy, can be immunosuppressive. However, multiple observations have shown that under appropriate conditions of dose separation and sequencing, radiotherapy can enhance tumor-specific immune responses as well as the effects of immunomodulators. One of several mechanisms leading to this effect is cross-presentation of tumor antigens released by radiation-induced tumor cell death by dendritic cells and other antigen-presenting cells (Higgins et al., Cancer Biol. Ther. 8: 1440-1449 (2009)). In effect, radiation therapy can induce in situ vaccination against tumors (Ma et al., Seminar Immunol. 22: 113-124 (2010)) and this can be amplified by combining therapy with SEMA4D or plexin-B1 binding molecules, such as antibodies or antigen-binding fragments, variants or derivatives thereof.
[0146] In one embodiment, immunomodulatory therapy can be an immunomodulator, including but not limited to interleukins such as IL-2, IL-7, IL-12; cytokines such as granulocyte colony stimulating factor (G-CSF), interferon; various chemokines such as CXCL13, CCL26, CXCL7; antagonists of immune checkpoint blockade, such as anti-CTLA-4, anti-PD1 or anti-PD-L1, anti-LAG3 and anti-B7-H3; synthetic cytosine phosphate-guanine (CpG), oligodeoxynucleotides, dextran, regulators of regulatory T cells (Treg) such as cyclophosphamide, or other immunomodulators. In one embodiment, the immunomodulator is an antagonist antibody (CD137) against 4-1BB. As recently reported, this type of antagonist antibody against 4-1BB can produce a new type of KLRG1+T cells, which are highly cytotoxic to tumors (Curran et al., J. Exp. Med. 210: 743-755 (2013)). In all cases, the other immunomodulatory treatment is administered before, during or after the anti-SEMA4D or anti-plexin-B1 binding molecule, e.g., antibody, or antigen-binding fragment, variant or derivative thereof therapy. In cases where the combination therapy comprises administration of an anti-SEMA4D binding molecule, e.g., antibody, or antigen-binding fragment, variant or derivative thereof, and administration of another immunomodulatory agent, the methods of the invention include co-administration, use of separate formulations or a single pharmaceutical formulation, which are administered simultaneously or sequentially in any order.
[0147] In one embodiment, the immunomodulatory therapy can be a cancer therapeutic agent, including but not limited to surgery or surgical procedures (e.g., splenectomy, hepatectomy, lymphadenectomy, leukophoresis, bone marrow transplantation, etc.); radiation therapy; chemotherapy, optionally in combination with autologous bone marrow transplantation or other cancer therapies; wherein the other cancer therapy is administered before, simultaneously or after the anti-SEMA4D binding molecule, e.g., antibody or antigen-binding fragment, variant or derivative thereof. In the case where the combination therapy includes administration of an anti-SEMA4D binding molecule, e.g., antibody or antigen-binding fragment, variant or derivative thereof and administration of another treatment, the methods of the invention include co-administration, use of separate formulations or a single pharmaceutical formulation, simultaneous or sequential administration in any order.
[0148] In another embodiment, the present invention relates to the use of anti-SEMA4D or anti-plexin-B1 binding molecules, e.g., antibodies, including antigen-binding fragments, variants and derivatives thereof as a single agent or in combination with at least one other immunomodulatory therapy to treat cancer patients with elevated levels of circulating B cells, T cells, or B cells and T cells compared to other solid tumor patients (such as those found in the brain, ovary, breast, colon and other tissues, but excluding blood cancers). The term "elevated" as used herein refers to the average number of circulating B cells and / or T cells in cancer patients being at least 1.5 times that of other cancer patients, e.g., about 1.5 to about 5 times, e.g., about 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 or more times. In a non-limiting example, in a group of 34 solid tumor patients, the average number of B cells was 98 per microliter of blood, and the average number of T cells was 782 per microliter of blood. Thus, the average number of B cells and T cells per microliter of blood observed in this subgroup of cancer patients with elevated B cell and T cell levels can range from about 147 to about 588 and from about 1173 to about 3910, respectively, compared to other cancer patients.
[0149] In another embodiment, the present invention relates to the use of anti-SEMA4D or anti-plexin-B1 binding molecules, e.g., antibodies, including antigen-binding fragments, variants and derivatives thereof as a single agent or in combination with at least one other immunomodulatory therapy to treat patients with circulating B cells, T cells, or B cells and T cell levels that fall within the normal individual range or above the range. The term "normal" as used herein refers to the B and / or T cell levels found in healthy non-cancer patients. The term "falling into" as used herein refers to a 10% difference in B cell and / or T cell levels. In a non-limiting embodiment, the range of normal levels includes, for example, a B cell amount of about 250 cells or more per microliter and / or a T cell amount of about 1500 cells or more per microliter. Therefore, compared to other healthy non-cancer patients, the average number of B cells and T cells per microliter of blood observed in cancer patients with elevated B cell and T cell levels can range from about 225 to about 275 or more and from about 1350 to about 1650 and more, respectively. Of course, one skilled in the art will appreciate that the levels of B cells and T cells may vary depending on a variety of factors, e.g., cancer type, cancer stage, etc., and thus, levels below the ranges provided above may also constitute elevated levels for certain types or stages of cancer.
[0150] In some embodiments, absolute T and B cell counts are measured using a validated flow cytometry-based immunophenotyping test (BD Mutitest6-color TBNK reagent), which is a six-color direct immunofluorescence test that also uses BD Trucount tubes and BD FACScanto flow cytometers. This test is typically used to determine the CD4 and CD8 subsets of T cells in peripheral blood and the absolute counts and percentages of T, B and NK cells. Peripheral blood cells are first gated on CD45+ lymphocytes. T cells are defined as CD3+ cells in this gate and B cells are defined as CD19+CD3- cells in this gate. After setting the appropriate gate, percentages are simply obtained directly from the flow cytometer, and absolute counts are calculated using the following formula (directly taken from the BD process manual): [(# events in the cell population / # events in the absolute count bead area)] * [(# beads / test a) / test volume] = absolute counts of cell populations, where "a" is the value found on the BD Trucount tube foil bag label.
[0151] It should also be understood that the methods described herein are also applicable to the replacement of anti-plexin-B1 binding molecules with anti-SEMA4D binding molecules. In some embodiments, anti-plexin-B1 binding molecules can be used to inhibit the interaction of SEMA4D with plexin-B1 by blocking the binding of SEMA4D to plexin-B1 and / or by preventing SEMA4D from activating plexin-B1. It should also be understood that the methods described herein are also applicable to the use of small molecule drugs or other biological products to inhibit the activity of SEMA4D or plexin-B1. In some embodiments, small molecule drugs or biological products other than anti-plexin-B1 binding molecules can be used to inhibit the interaction of SEMA4D with plexin-B1 by blocking the binding of SEMA4D to plexin-B1 and / or by preventing SEMA4D from activating plexin-B1.
[0152] In one embodiment, treatment comprises applying or administering an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment described herein, to a patient as a single agent or in combination with at least one other immunomodulatory therapy, or applying or administering an anti-SEMA4D binding molecule to an isolated tissue or cell line from a patient as a single agent or in combination with at least one other immunomodulatory therapy, wherein the patient has, or is at risk of developing cancer cells from metastases. In another embodiment, treatment also tends to comprise administering a composition comprising an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment thereof, to a patient in combination with at least one other immunomodulatory therapy, or applying or administering a composition comprising an anti-SEMA4D binding molecule and at least one other immunomodulatory therapy to an isolated tissue or cell line from a patient, wherein the patient has, or is at risk of developing cancer cells from metastases.
[0153] The anti-SEMA4D binding molecules described herein, such as antibodies or binding fragments thereof, can be used to treat a variety of malignant and non-malignant tumors as a single agent or in combination with at least one other immunomodulatory therapy. "Anti-tumor activity" refers to a reduction in the rate of SEMA4D production or accumulation directly associated with the tumor or indirectly associated with the stromal cells of the tumor environment, and thus reducing the growth rate of existing tumors or tumors that appear during treatment, and / or destroying existing tumor cells or newly formed tumor cells, and thus reducing the size of the tumor and / or the number of metastatic sites during treatment. For example, treatment with an anti-SEMA4D antibody in the form of a single agent or in combination with at least one other immunomodulatory therapy results in a physiological response, such as a reduction in metastatic cancer, which is beneficial relative to the treatment of a disease state associated with SEMA4D-expressing cells in humans.
[0154] In one embodiment, the invention relates to the use of an anti-SEMA4D binding molecule, such as an antibody or an antigen-binding fragment, variant or derivative thereof, as a single agent or in combination with at least one other immunomodulatory therapy as a drug for treating or preventing cancer or for inhibiting, reducing, preventing, delaying or minimizing the growth or metastasis of tumor cells in precancerous conditions or lesions.
[0155] According to the methods of the present invention, at least one anti-SEMA4D binding molecule, such as an antibody or an antigen-binding fragment, variant or derivative thereof, in the form of a single agent or in combination with at least one other immunomodulatory treatment can be used to promote a positive therapeutic response against malignant human cells. A "positive therapeutic response" for cancer treatment refers to a disease improvement associated with the anti-tumor activity of these binding molecules, such as antibodies or fragments thereof, and / or an improvement in disease-related symptoms. Specifically, the methods provided by the present invention relate to inhibiting, preventing, reducing, alleviating, delaying or attenuating tumor growth and / or the development of primary tumors into metastatic tumors in patients. That is, it can be observed that distal tumor derivation is prevented. Thus, for example, disease improvement is characterized by a complete response. "Complete response" refers to a radiographic study of abnormalities before standardization, for example, when there are tumor metastases at the primary tumor site or in the bone marrow, there are no clinically detectable metastatic cancers. Alternatively, disease improvement can be classified as a partial response. "Partial response" refers to a reduction of at least about 50% in all measurable metastatic cancers (i.e., the number of tumor cells present at a site away from the primary tumor in the subject). Alternatively, disease improvement can be classified as recurrence-free survival or "progression-free survival". "Relapse-free survival" refers to the time until a tumor reappears at any site. "Progression-free survival" is the time before further growth of the tumor at the monitored site can be detected.
[0156] Scanning counts, such as imaging, e.g., fluorescent antibody imaging, bone scan imaging, and tumor biopsy sampling including bone marrow aspiration (BMA), or immunohistochemistry can be used to evaluate the inhibition, delay or reduction of metastatic cancer. In addition to these positive treatment responses, subjects treated with anti-SEMA4D binding molecules, such as antibodies or antigen-binding fragments, variants or derivatives thereof, may experience beneficial effects of improved disease-related symptoms.
[0157] Clinical response can be assessed using screening techniques such as magnetic resonance imaging (MRI) scans, x-ray imaging, computed tomography (CT) scans, flow cytometry or fluorescence activated cell sorter (FACS) analysis, histological analysis, gross pathological analysis, and blood chemistry analysis, including but not limited to changes detectable by ELISA, RIA, chromatography, and the like.
[0158] To apply the methods and systems of the present invention in certain embodiments, a sample may be obtained from a patient before or after a subject having a tumor that is Her2+ and Plexin B1+ or Plexin B2+ is given a treatment comprising: (1) an effective amount of an isolated binding molecule that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment; or (2) an effective amount of an isolated binding molecule that specifically binds to semaphorin-4D (SEMA4D). In some cases, serial samples may be obtained from a patient after treatment has begun or after treatment has ceased. The sample may be, for example, requested by a medical provider (e.g., a physician) or a health care provider, obtained and / or processed by the same or different medical provider (e.g., a nurse, a hospital) or a clinical laboratory, and after processing, the results may be forwarded to another provider, health care provider, or patient. Similarly, measurement / determination of one or more scores, comparisons between scores, evaluation of scores, and treatment decisions may be performed by one or more medical providers, health care providers, and / or clinical laboratories.
[0159] As used herein, the term "medical provider" refers to an individual or institution that directly contacts or administers medication to a living subject (e.g., a human patient). Non-limiting examples of medical providers include doctors, nurses, technicians, therapists, pharmacists, counselors, alternative medicine practitioners, medical facilities, doctors' offices, hospitals, emergency rooms, clinics, emergency centers, alternative medicine clinics / facilities, and any other entity that provides general and / or special treatment, evaluation, maintenance, therapy, medicine, and / or advice regarding all or any part of a patient's health status, including, but not limited to, general medicine, special medicine, surgery, and / or any other type of treatment, evaluation, maintenance, therapy, medicine, and / or advice.
[0160] In some aspects, a medical provider may administer or instruct other medical providers to administer a treatment to a subject having or suspected of having tumor cells that are Her2+ and Plexin B1+ or Plexin B2+, the treatment comprising: (1) an effective amount of an isolated binding molecule that specifically binds to Semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment; or (2) an effective amount of an isolated binding molecule that specifically binds to Semaphorin-4D (SEMA4D). A medical provider may perform or instruct other medical providers or patients to perform the following actions: obtain a sample, process a sample, submit a sample, receive a sample, transfer a sample, analyze or measure a sample, quantify a sample, provide a result obtained after analyzing / measuring / quantifying a sample, receive a result obtained after analyzing / measuring / quantifying a sample, compare / score a result obtained after analyzing / measuring / quantifying one or more samples, provide a comparison / score from one or more samples, obtain a comparison / score from one or more samples, administer a treatment to a subject (e.g., (1) an effective amount of an isolated binding molecule that specifically binds to Semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatments; or (2) an effective amount of an isolated binding molecule that specifically binds to semaphorin-4D (SEMA4D)), wherein the subject has, or is suspected of having, tumor cells that are Her2+ and plexin B1+ or plexin B2+, starts treatment, stops treatment, continues treatment, temporarily interrupts treatment, increases the amount of therapeutic agent administered, decreases the amount of therapeutic agent administered, continues to administer a certain amount of therapeutic agent, increases the frequency of administration of the therapeutic agent, decreases the frequency of administration of the therapeutic agent, maintains the same dosing frequency of the therapeutic agent, replaces the treatment or therapeutic agent with at least one other treatment or therapeutic agent, or combines the treatment or therapeutic agent with at least one other treatment or therapeutic agent. In some aspects, a medical provider may authorize or deny, for example, collecting a sample, processing a sample, submitting a sample, receiving a sample, transferring a sample, analyzing or measuring a sample, quantifying a sample, providing results obtained after analyzing / measuring / quantifying a sample, transferring results obtained after analyzing / measuring / quantifying a sample, comparing / scoring results obtained after analyzing / measuring / quantifying one or more samples, transferring comparisons / scores from one or more samples, administering a treatment or therapeutic agent, starting administration of a treatment or therapeutic agent, stopping administration of a treatment or therapeutic agent, continuing administration of a treatment or therapeutic agent, temporarily interrupting administration of a treatment or therapeutic agent, increasing the amount of a therapeutic agent administered, decreasing the amount of a therapeutic agent administered, continuing administration of a certain amount of a therapeutic agent, increasing the frequency of administration of a therapeutic agent, decreasing the frequency of administration of a therapeutic agent, maintaining the same dosing frequency of a therapeutic agent, replacing a treatment or therapeutic agent with at least one other treatment or therapeutic agent, or combining a treatment or therapeutic agent with at least one other treatment or therapeutic agent.
[0161] Additionally, the health care benefits provider may, for example, authorize or deny prescription of treatment, authorize or deny coverage of treatment, authorize or deny reimbursement of treatment costs, determine or deny treatment eligibility, and the like.
[0162] In some aspects, a clinical laboratory can, for example, collect or obtain samples, process samples, submit samples, receive samples, transfer samples, analyze or measure samples, quantify samples, provide results obtained after analyzing / measuring / quantifying samples, receive results obtained after analyzing / measuring / quantifying samples, compare / score results obtained after analyzing / measuring / quantifying one or more samples, provide comparisons / scores from one or more samples, obtain comparisons / scores from one or more samples, or other related activities.
[0163] VI. Diagnosis and treatment methods
[0164] In certain embodiments, the present invention provides a method for treating an object, such as a cancer patient, wherein the object has an elevated level of B cells, T cells, or B cells and T cells, the method comprising administering an effective amount of a combination of a combination of a specific binding semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment if the B cell, T cell, or B cell and T cell level of the object exceeds a predetermined threshold level of B cells, T cells, or B cells and T cells, or increases relative to the B cell, T cell, or B cell and T cell level in one or more control samples, the control sample may include, but is not limited to, samples from other cancer patients or from healthy non-cancer patients. B cells, T cells, or B cells and T cells levels can be measured by a medical provider or clinical laboratory, wherein a sample, such as a blood sample, is obtained from a patient by a medical provider or clinical laboratory. In one aspect, the level of a patient's B cells, T cells, or B cells and T cells can be measured in an immunophenotyping assay based on flow cytometry.
[0165] In certain embodiments, the present invention also provides a method for treating a subject, such as a cancer patient, comprising: if the expression of Her2 and plexin B1 or plexin B2 in a sample of tumor cells taken from the subject is higher than the above-mentioned predetermined threshold level, or the expression of Her2 and plexin B1 or plexin B2 in one or more control samples is increased, then the subject is given an effective amount of a separated binding molecule that specifically binds to brain signal protein-4D (SEMA4D). The expression of Her2, plexin B1 and / or plexin B2 in the tumor cells of the subject can be measured at the protein level and / or mRNA level by a medical provider or a clinical laboratory. In certain aspects, the expression of Her2, plexin B1 and / or plexin B2 can be measured in situ by, for example, imaging technology. In certain aspects, the expression of Her2, plexin B1 and / or plexin B2 in the tumor cell sample of the subject can be measured by biopsy. In one aspect, Her2, plexin B1 and / or plexin B2 expression in tumor cells can be measured in a bioassay using an antibody or antigen binding fragment thereof that recognizes Her2, plexin B1, and / or plexin B2 proteins, or antigen binding fragments, variants or derivatives thereof. In another aspect, Her2, plexin B1 and / or plexin B2 expression can be measured by a quantitative gene expression assay, such as an RT-PCR assay.
[0166] The present invention also provides methods, assays and kits to facilitate the determination by a medical provider, a medical benefit provider or a clinical laboratory whether a subject, such as a cancer patient, would benefit from treatment with: (1) an effective amount of an isolated binding molecule that specifically binds to Semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment; or (2) an effective amount of an isolated binding molecule that specifically binds to Semaphorin-4D (SEMA4D), wherein the subject has or is suspected of having tumor cells that are Her2+ and Plexin B1+ or Plexin B2+. The present invention also provides methods, assays and kits to facilitate the determination by a medical provider, a medical benefit provider or a clinical laboratory whether a subject, such as a cancer patient, would benefit from treatment with: (1) an effective amount of an isolated binding molecule that specifically binds to Semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment; or (2) an effective amount of an isolated binding molecule that specifically binds to Semaphorin-4D (SEMA4D) (e.g., wherein the subject's tumor cells express or are determined to express Her2 and Plexin B1 or Plexin B2).
[0167] The present invention provides a method for treating a subject, such as a cancer patient, comprising administering an effective amount of an isolated binding molecule that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment if the level of B cells, T cells, or B cells and T cells in a sample taken from the patient is above a predetermined threshold level, or is above the level of B cells, T cells, or B cells and T cells in one or more control samples. In some aspects, a sample is obtained from a patient and submitted to, for example, a clinical laboratory to measure the level of B cells, T cells, or B cells and T cells in the sample.
[0168] Also provided is a method for treating a subject, such as a cancer patient, comprising: (a) submitting a sample taken from the subject to measure the level of B cells, T cells, or B cells and T cells in the sample; and (b) if the level of B cells, T cells, or B cells and T cells in the subject is above a predetermined threshold level, or above the level of B cells, T cells, or B cells and T cells in one or more control samples, administering to the subject an effective amount of an isolated binding molecule that specifically binds to brain semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory therapy.
[0169] The present invention also provides a method for treating a subject, such as a cancer patient, comprising (a) measuring the level of B cells, T cells, or B cells and T cells in a sample taken from a subject, such as a cancer patient, wherein the level of B cells, T cells, or B cells and T cells in the sample is measured in a flow cytometry-based immunophenotyping assay; (b) determining whether the level of B cells, T cells, or B cells and T cells in the sample is above a predetermined threshold level, or is higher than the level of B cells, T cells, or B cells and T cells in one or more control samples; and (c) if the level of B cells, T cells, or B cells and T cells in the subject is above a predetermined threshold level, or is higher than the level of B cells, T cells, or B cells and T cells in one or more control samples, recommending, instructing or authorizing a medical provider to administer an effective amount of an isolated binding molecule that specifically binds to brain semaphorin-4D (SEMA4D) and an effective amount of at least one other immunomodulatory treatment to the subject.
[0170] In some aspects, the level of B cells, T cells, or B cells and T cells of the object can be measured in the immunophenotypic test based on flow cytometry. In some aspects, the sample taken from the object can be tested by a medical professional with a test such as described herein configured as a "point of care" diagnostic kit. In some aspects, a sample can be obtained from the object and can be submitted to, for example, a clinical laboratory to measure the level of B cells, T cells, or T cells and B cells in the sample according to the instructions of the medical professional, including but not limited to the immunophenotypic test based on flow cytometry described herein. In some aspects, the test performed by the clinical laboratory can suggest that a medical provider or a medical benefit provider if the level of B cells, T cells, or B cells and T cells in the sample taken from the patient is higher than a predetermined threshold level, or higher than the level of B cells, T cells, or T cells and B cells in one or more control samples, whether the object benefits from the treatment of at least one other immunomodulatory treatment of the separation of the binding molecule of the specific binding brain signal protein-4D (SEMA4D) with an effective amount and an effective amount.
[0171] In certain aspects, the results of the immunoassays provided herein can be submitted to a healthcare benefit provider to determine whether a patient's insurance covers treatment with an isolated binding molecule that specifically binds Semaphorin-4D (SEMA4D) and at least one other immunomodulatory therapy.
[0172] VII. Pharmaceutical Compositions and Methods of Administration
[0173] Methods for preparing and administering anti-SEMA4D binding molecules, such as antibodies or antigen-binding fragments, variants or derivatives thereof, in single agent form or in combination with at least one other immunomodulatory therapy are well known or readily determined by those skilled in the art. The route of administration of anti-SEMA4D binding molecules, such as antibodies or antigen-binding fragments, variants or derivatives thereof, in single agent form or in combination with at least one other immunomodulatory therapy may be, for example, oral, parenteral, by inhalation or topical administration at the same or different times for each therapeutic agent. The term "parenteral" as used herein includes, for example, intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal or vaginal administration. Although all of these administration forms are clearly considered to be within the scope of the present invention, an example of an administration form is an injection, particularly for intravenous or intraarterial injection or infusion. Suitable pharmaceutical compositions for injection may include a buffer (such as an acetate, phosphate or citrate buffer), a surfactant (such as a polysorbate), and optionally a stabilizer (such as human albumin), etc. However, in other methods consistent with the teachings herein, an anti-SEMA4D binding molecule of the invention, such as an antibody or antigen-binding fragment, variant or derivative thereof, as a single agent or in combination with at least one other immunomodulatory treatment can be delivered directly to the site of the undesirable cell population, thereby increasing contact of the diseased tissue with the therapeutic agent.
[0174] As described herein, the anti-SEMA4D binding molecules of the present invention, such as antibodies or antigen-binding fragments, variants or derivatives thereof, in a single agent form or in combination with at least one other immunomodulatory therapy can be administered in a pharmaceutically effective amount for in vivo treatment of diseases, such as neoplastic diseases, including solid tumors. In this regard, it should be understood that the binding molecules disclosed in the present invention will be formulated to facilitate administration and improve the stability of the active substance. In certain embodiments, the pharmaceutical compositions of the present invention comprise a pharmaceutically acceptable non-toxic sterile carrier, such as physiological saline, non-toxic buffer, preservatives, etc. For the purposes of this application, a pharmaceutically effective amount of an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, in a single agent form or in combination with at least one other immunomodulatory therapy should be considered to be sufficient to bind to the target and achieve inhibition, delay or reduction of metastatic cancer in cancer patients.
[0175] The pharmaceutical composition used in the present invention comprises a pharmaceutically acceptable carrier, including, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.
[0176] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous vehicles include, for example, water, alcohol / water solutions, emulsions or suspensions, including saline and buffered media. Pharmaceutically acceptable vehicles include, but are not limited to, 0.01-0.1M, for example, 0.05M phosphate buffer or 0.8% saline. Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's solution or fixed oils. Intravenous vehicles include fluid and nutrient supplements, electrolyte supplements, such as those based on Ringer's dextrose, etc. Preservatives and other additives may also be present, for example, antimicrobial agents, antioxidants, chelating agents, and inert gases, etc.
[0177] More specifically, pharmaceutical compositions suitable for injection applications include sterile aqueous solutions (when water-soluble) or dispersions, and sterile powders for extemporaneous preparation of sterile injections or dispersions. In this case, the composition must be sterile and should be a fluid that has an easy syringability to inject. It should be stable under manufacturing and storage conditions, and should be able to resist the contamination of microorganisms such as bacteria and fungi during storage. The carrier can be a solvent or dispersion medium containing water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.) and suitable mixtures thereof. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining a specific particle size in the case of a dispersion, and by using a surfactant. Preparations suitable for the treatment methods described herein can be found in Remington's Pharmaceutical Sciences (Mack Publishing Co.), 16th edition (1980).
[0178] The prevention of microbial action can also be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.). In certain embodiments, isotonic agents may be included in the composition, for example, sugars, polyols, such as mannitol, sorbitol, or sodium chloride. Agents that delay absorption (e.g., aluminum monostearate and gelatin) may be included in the composition to prolong the absorption of the injectable composition.
[0179] In any case, the preparation of a sterile injectable solution can be by incorporating a specific amount of an active compound (such as an anti-SEMA4D antibody or an antigen-binding fragment, variant or derivative thereof, itself or in combination with at least one other immunomodulatory treatment) into a suitable solvent containing one or more components listed herein, and then filtering and sterilizing. Typically, the active active substance is incorporated into a sterile carrier containing an alkaline dispersion medium and the above-mentioned other ingredients to prepare a dispersion. When preparing a sterile powder required for a sterile injection, the preparation method may include vacuum drying or freeze drying, and a powder of the active ingredient and any other desired components can be produced from a previously sterile filtered solution. The injection preparation is processed under aseptic conditions according to methods known in the art, loaded into a container (such as an ampoule, bag, bottle, syringe or tube), and sealed. In addition, the preparation can be packaged and sold in the form of a kit. Such products may have a label or drug instructions indicating that the relevant composition can be used to treat subjects suffering from or prone to a disease or condition.
[0180] Parenteral formulations may be a single bolus dose, an infusion or a loading bolus dose followed by a maintenance dose. These compositions may be administered at specific fixed or variable intervals, for example, once daily or on an "as needed" basis.
[0181] Certain pharmaceutical compositions can be administered orally in acceptable dosage forms, including, for example, capsules, tablets, aqueous suspensions or solutions. Certain pharmaceutical compositions can also be administered by nasal aerosol or inhalation. Such compositions can be prepared as saline solutions using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioaccessibility, and / or other conventional solubilizing agents or dispersants.
[0182] The amount of the anti-SEMA4D binding molecule, such as an antibody or its antigen-binding fragment, variant or derivative to be combined with a carrier material to produce a single agent form of a single dosage form or in combination with at least one other immunomodulatory treatment will vary depending on the host being treated and the specific mode of administration. The composition can be administered in a single dosage form, multiple dosage forms, or in an infusion over an established time period. The dosage regimen can also be adjusted to provide the optimal desired response (e.g., a therapeutic or preventive response).
[0183] Within the scope of the present invention, an anti-SEMA4D antibody or its antigen-binding fragment, variant or derivative in single agent form or in combination with at least one other immunomodulatory treatment can be administered to a human or other animal in accordance with the above-described treatment methods, and the amount administered is sufficient to produce a therapeutic effect. An anti-SEMA4D antibody or its antigen-binding fragment, variant or derivative in single agent form or in combination with at least one other immunomodulatory treatment can be administered to a human or other animal in a conventional dosage form, prepared by combining the antibodies provided herein with conventional pharmaceutically acceptable carriers or diluents according to known techniques. Those skilled in the art will recognize that the form and characteristics of the pharmaceutically acceptable carrier or diluent are determined by the content of the active ingredient mixed, the route of administration and other well-known variables. Those skilled in the art will also understand that a mixture containing one or more anti-SEMA4D binding molecules, such as antibodies or their antigen-binding fragments, variants or derivatives provided by the present invention, can be used.
[0184] A "therapeutically effective dose or amount" or "effective amount" refers to an amount of an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, that, when administered, results in a positive therapeutic response in a patient suffering from the disease being treated, e.g., inhibiting, delaying or reducing metastatic cancer in the patient, either as a single agent or in combination with at least one other immunomodulatory therapy.
[0185] The therapeutically effective dose of the pharmaceutical preparation of the present invention for inhibiting, delaying or reducing metastatic cancer can vary according to many different factors, including the mode of administration, the target site, the physiological state of the patient, whether the patient is a human or an animal, other drugs administered, and whether the treatment is preventive or therapeutic. In certain embodiments, the patient is a human, but non-human mammals, including transgenic mammals, can also be treated. Conventional methods known to those skilled in the art can be used to titrate the therapeutic dose to optimize safety and efficacy.
[0186] The amount of an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, to be administered as a single agent or in combination with at least one other immunomodulatory therapy is readily determined by one of ordinary skill in the art without requiring undue experimentation as provided herein. Factors affecting the respective amounts and modes of administration of an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, administered as a single agent or in combination with at least one other immunomodulatory therapy include, but are not limited to, the severity of the disease, medical history, likelihood of metastasis, age, height, weight, health and physical condition of the individual being treated. Similarly, the amount of an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, to be administered as a single agent or in combination with at least one other immunomodulatory therapy will depend on the mode of administration and whether the patient will receive a single dose or multiple doses of the agent.
[0187] The present invention also provides for the use of an anti-SEMA4D binding molecule, such as an antibody or an antigen-binding fragment, variant or derivative thereof, as a single agent or in combination with at least one other immunomodulatory therapy, in the preparation of a medicament for treating a cancer patient, wherein the medicament is for a subject that has been pretreated with at least one other therapy. "Pretreatment" or "pretreatment" means that the subject has received one or more other treatments (e.g., has been treated with at least one other cancer therapy) prior to receiving a medicament comprising an anti-SEMA4D binding molecule, such as an antibody or an antigen-binding fragment, variant or derivative thereof, as a single agent or in combination with at least one other immunomodulatory therapy. "Pretreatment" or "pretreatment" includes subjects who have been treated with at least one other treatment within 2 years, 18 months, 1 year, 6 months, 2 months, 6 weeks, 1 month, 4 weeks, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, or even 1 day of starting treatment with a drug comprising an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, either alone or in combination with at least one other immunomodulatory treatment. The subject does not have to have responded to pretreatment with one or more previous treatments. Thus, a subject receiving a drug comprising an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, either alone or in combination with at least one other immunomodulatory treatment may or may not have responded to pretreatment with a previous treatment, or one or more of the previous treatments where the pretreatment included multiple treatments (e.g., refractory cancer). Examples of other cancer therapies that a subject may have previously been treated with before receiving a medicament comprising an anti-SEMA4D binding molecule, such as an antibody or antigen-binding fragment, variant or derivative thereof, either alone or in combination with at least one other immunomodulatory therapy include, but are not limited to, surgery; radiation therapy; chemotherapy, optionally in combination with autologous bone marrow transplantation, where suitable chemotherapeutic agents include, but are not limited to, those listed above; other anti-cancer monoclonal antibody therapies; small molecule-based cancer therapies, including, but not limited to, the small molecules listed above; vaccine / immunotherapy-based cancer therapies; steroid therapy; other cancer therapies; or any combination thereof.
[0188] Unless otherwise indicated, the practice of the present invention will employ conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA and immunology, which are within the skill of the art and are fully described in the literature. See, e.g., Sambrook et al., eds. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press); Sambrook et al., eds. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); D. N. Glover, ed. (1985) DNA Cloning, Vols. I and II; Gait, ed. (1984) Oligonucleotide Synthesis; Mullis et al., U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan R. Liss, Inc.) (ARL); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To Molecular Cloning (Practical Guide to Molecular Cloning); Paper, Methods In Enzymology (Academic Press, Inc.Miller and Calos, eds. (1987) Gene Transfer Vectors For Mammalian Cells (Cold Spring Harbor Laboratory); Wu et al., eds., Methods In Enzymology, Vols. 154 and 155; Mayer and Walker, eds. (1987) Immunochemical Methods In Cell And Molecular Biology (Academic Press, London); Weir and Blackwell, eds. (1986) Handbook Of Experimental Immunology, Vols. I-IV; Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1986); and Ausubel et al. (1989) Current Protocols in Molecular Biology. Biology (New Molecular Biology Laboratory Manual) (John Wiley & Sons, Baltimore, Md.).
[0189] General principles of antibody engineering can be found in Borrebaeck, ed. (1995) Antibody Engineering (2nd ed.; Oxford Univ. Press). General principles of protein engineering can be found in Rickwood et al., eds. (1995) Protein Engineering, A Practical Approach (IRL Press at Oxford Univ. Press, Oxford, Eng.). General principles of antibodies and antibody-hapten binding can be found in Nisonoff (1984) Molecular Immunology (2nd ed.; Sinauer Associates, Sunderland, Mass.); and Steward (1984) Antibodies, Their Structure and Function (Chapman and Hall, New York, NY). In addition, standard immunological procedures known in the art and not specifically described are generally performed as described in Current Protocols in Immunology, John Wiley & Sons, New York; Stites et al., eds. (1994) Basic and Clinical Immunology (8th ed.; Appleton and Lange, Norwalk, Conn.), and Mishell and Shiigi (eds.) (1980) Selected Methods in Cellular Immunology (WH Freeman and Co, New York).
[0190] Standard reference texts listing the general principles of immunology include: Current Protocols in Immunology, John Wiley & Sons, New York; Klein (1982) J., Immunology: The Science of Self-Nonself Discrimination (John Wiley & Sons, New York); Kennett et al., eds. (1980) Monoclonal Antibodies, Hybridoma: A New Dimension in Biological Analyses (Plenum Press, New York); Campbell (1984) "Monoclonal Antibody Technology" in Laboratory Techniques in Biochemistry and "Molecular Biology" ("Monoclonal Antibody Technology" in "Biochemistry and Molecular Biology Laboratory Techniques"), Burden et al., eds. (Elsevere, Amsterdam); Goldsby et al., eds. (2000) Kuby Immunnology (4th edition); H. Freeman & Co.)); Roitt et al. (2001) Immunology (6th ed.; London: Mosby); Abbas et al. (2005) Cellular and Molecular Immunology (5th ed.; Elsevier Health Sciences Division); Kontermann and Dubel (2001) Antibody Engineering (Springer Verlan); Sambrook and Russell (2001) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Press); Lewin (2003) Gene VIII (Prentice Hall 2003); Harlow and Lane (1988) Antibodies: A Laboratory Manual (Cold Spring Harbor Press); Manual (Antibodies: A Laboratory Manual) (Cold Spring Harbor Press); Dieffenbach and Dveksler (2003) PCR Primer (Cold Spring Harbor Press).
[0191] All references cited above and all references cited therein are incorporated herein by reference in their entirety.
[0192] The following examples are offered by way of illustration, not limitation. Example
[0193] Example 1: Testing the ability of the antibody-SEMA4D antibody to delay tumor growth in immunocompetent mice
[0194] Experimental design. The basic experimental design is as follows. Colon 26 tumor cells in 0.2 ml saline were implanted subcutaneously in the axilla of syngeneic immunocompetent Balb / c mice (5x10^5 cells) or immunodeficient SCID mice (1x10^5 cells). Treatment with control Ig 2B8 or anti-SEMA4D Ab 67 was initiated on day 2 after tumor implantation. Mice were treated twice a week (n=20) with 1.0 mg (approximately 50 mg / kg) of each monoclonal antibody by intraperitoneal (IP) injection. Tumors were measured 3 times a week with a caliper starting 3 days after implantation. Mice were weighed twice a week starting on day 3. When the tumor volume reached 1000 mm 3 Animals were killed at that time.
[0195] Anti-SEMA4D treatment delayed tumor growth in mice with an active immune system. Tumor growth was measured with calipers and the measurements were used to calculate the total tumor growth using the formula (w 2 Tumor volume was calculated as xl) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. The mean tumor volume was determined over time ( Figure 1A ) and Kaplan-Meier survival curves ( Figure 1B ), until the end point, where tumor volume = 1000 mm 3 ,like Figure 1A and 1B Statistical analysis was performed using two-way analysis of variance (ANOVA) and log-rank analysis, respectively, which showed a statistically significant treatment effect of anti-SEMA4D antibody in Balb / c mice.
[0196] A 29% tumor growth delay was achieved in Balb / c mice, however, no treatment-related tumor growth delay was observed in SCID mice. Tumor growth delay (TGD) was defined as the increase in median time-to-endpoint (TTE) in the treatment group compared to the control group: %TGD-[(TC) / C]x 100, T=median TTE of the treatment group, C=median TTE of the control group. At the time of sacrifice, Balb / c animals treated with anti-SEMA4D antibody 67 showed a statistically significant reduction in primary tumor volume compared to control animals (P<0.0001). This finding shows that anti-SEMA4D antibodies are effective in delaying tumor growth in mice with an active immune system, but not in immunodeficient mice.
[0197] Example 2: Testing the ability of anti-SEMA4D antibodies to delay tumor growth in the presence of CD8+ effector T cells
[0198] Experimental design. Colon 26 tumor cells were implanted subcutaneously in the axilla of Balb / c mice (5x10^5 cells in 0.2 ml saline). Anti-CD8 depleting antibody (Clone 2.43, BioXCell) or control rat Ig (Clone LTF-2, BioXCell) (150 mg / kg) was given by intraperitoneal (IP) injection on days -1, 0, 1, 11 and weekly thereafter. Treatment with control Ig2B8 or anti-SEMA4D Ab 67 was started on day 2. Mice were treated twice a week (n=20) with 1.0 mg (approximately 50 mg / kg) of the monoclonal antibody by intraperitoneal injection. Tumors were measured 3 times a week starting 3 days after implantation with a caliper. When the average tumor volume of the control group reached 1000 mm 3When the rat Ig-treated group was treated, the animals were sacrificed on day 30, and the anti-CD8-treated group was sacrificed on day 25.
[0199] Anti-SEMA4D treatment delayed tumor growth in the presence of CD8+ T lymphocytes. The growth was measured with a caliper and using the formula (w 2 Tumor volume was calculated by χ2 = 1 / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Two-tailed one-way analysis of variance (ANOVA) was used to compare the antibody-treated groups with the control Ig 2B8 group to determine statistical differences in tumor volume. The mean tumor volumes are shown in Figure 2 .
[0200] Inhibition of tumor growth was also determined. Tumor growth inhibition (TGI) was measured using the following formula: %TGI=1-[(Tf-Ti) / mean(Cf-Ci)]; the reported %TGI is the mean of the %TGI of each treated tumor. Two-tailed one-phase analysis of variance (ANOVA) was used, followed by Dunnett's multiple comparison test to compare the antibody-treated group and the control Ig 2B8 group to determine the statistical differences in tumor volume. 30% tumor growth inhibition was achieved after treatment with anti-SEMA4D antibody, however no treatment-related effects were observed when CD8+T cells were depleted. These results show that tumor growth inhibition with anti-SEMA4D depends on the presence of CD8+ effector T cells.
[0201] Example 3: Testing the ability of anti-SEMA4D antibodies to increase the density of tumor infiltrating lymphocytes (TILs)
[0202] Experimental design. Colon 26 tumor cells were implanted subcutaneously in the axilla of Balb / c mice (5x10^5 cells in 0.2 ml saline). Treatment with control Ig 2B8 or anti-SEMA4D Ab 67 (50 mg / kg IP, 2 times per week, n=10) was started on day 2. Tumors were measured 3 times per week with a caliper starting 3 days after implantation. When the mean tumor volume of the control group reached 1000 mm 3 Animals were sacrificed on day 27. Tumors including surrounding stroma and skin were collected and fixed in formalin for 24 hours and then transferred to 70% ethanol. Samples were then processed for paraffin embedding and 5 micron sections were cut from the resulting blocks.
[0203] Adjacent sections were stained for Sema4D, CD8, and CD20 using the following method:
[0204] For Sema4D detection, slides were baked at 60°C for 1 hour and then deparaffinized and dehydrated through xylene and gradient ethanol baths. Epitope retrieval was performed by boiling with target retrieval solution (Dako, Carpinteria, CA) for 20 minutes followed by cooling for 30 minutes. Slides were washed twice with PBS containing 0.05% Tween-20 (TPBS) and endogenous peroxidase was inactivated by blocking with a dual enzyme blocker (Dako, Carpinteria, CA) for 10 minutes. Slides were washed twice with TPBS and nonspecific binding was blocked by incubation with 2.5% normal goat serum in TPBS for 20 minutes. After a single TPBS wash, incubation was performed with 2 μg / ml rabbit anti-Sema4D in TPBS for 60 minutes followed by two washes with TPBS. Slides were then incubated with Envision HRP-conjugated goat anti-rabbit polymer (Dacron, Capitola, CA) for 20 min, followed by 2 washes with TPBS and 5 min incubation with DAB+ (Dacron, Capitola, CA). Sections were counterstained with Harris hematoxylin, destained, blued with tap water, dehydrated, and mounted nonaqueously with Permount.
[0205] The above method was used, but CD8 was detected using 2 μg / ml of a commercial rabbit polyclonal antibody (Abbiotec).
[0206] The above method was used, but normal donkey serum was used for blocking, and CD20 was detected using 1 μg / ml goat anti-CD20 primary antibody (Santa Cruz) followed by incubation with HRP-labeled anti-goat antibody (GoldenBridge) for 20 minutes.
[0207] Slides were imaged at 20X magnification using a Retiga QICAM-12-bit camera coupled to an Olympus IX50.
[0208] Anti-SEMA4D treatment increases the frequency of tumor infiltrating immune cells (TIL). By scanning the sections of the whole tumor, CD8+ or CD20+ tumor infiltrating lymphocytes (TIL) are quantified and then the total tumor area is standardized to measure the density of immune cells. Sections from 9 (control Ig) or 10 (anti-SEMA4D Ab 67) mice in each group are used for analysis. The statistical difference of CD8 and CD20 is calculated using a two-tailed unpaired T test to reach 95% CI.
[0209] Treatment of Colon 26 tumors with anti-SEMA4D antibody 67 resulted in an increase in both CD8+ T cell density and CD20+ T cell density compared to the control group. The increase in CD20+ T cell density was statistically significant at 95% with a P value of 0.0388. The increase in CD8+ T cell density showed a trend but was not statistically significant. These findings suggest that anti-SEMA4D treatment of Colon 26 tumors resulted in an increase in the frequency of tumor-infiltrating immune cells. The results are shown in Figure 3A and 3B .
[0210] Example 4: Testing of the effect of anti-SEMA4D antibodies on the distribution and migration of CD8+ T cells and M1 and M2 macrophage subsets at the tumor leading edge.
[0211] Anti-SEMA4D treatment changes the distribution of macrophages and CD8+T cells at the front edge of the tumor. By scanning the sections of the entire tumor, quantitative M1 (stained with 2 μg / ml of Alexa647-coupled rat anti-F4 / 80 (Biolegend, clone BM8)) and M2 (stained with 2 μg / ml of biotin-coupled rat anti-CD206 (Biolegend, clone C068C2)) area and then standardizing the total tumor area to determine the density of M1 and M2 in the tumor to measure macrophage distribution. Use sections from 9 (control Ig) or 10 (anti-SEMA4D Ab 67) treated mice in each group for analysis. In order to determine the cell density at the front end of tumor growth, a region of 300 pixels in width (250 microns) was defined from the edge of the tumor. The statistical significance of M1 and M2 was calculated using a single-phase ANOVA with a K-Warren test and a Dunnett post-test to reach 95% CI. The change in density of M1 macrophages normalized to the tumor leading edge was significant.
[0212] The number of CD8+T cells was measured in whole tumor sections stained with anti-CD8 antibody (Abbiotec lot 250596 at 1:250) and DAB detection system. The number of CD8+ events in whole tumor sections was counted after thresholding the positive signal using Imagepro software. The CD8+ density of each animal was calculated by dividing the number of CD8+ events by the whole tumor pixel immunity. Individual CD8 densities were averaged to obtain the distribution of CD8+T cells in animals (n=10) treated with 2B8 and mAb67. Statistical significance was calculated using a one-phase ANOVA with a K-Walter test and a Dunnett post-test to reach 95% CI.
[0213] SEMA4D distribution was measured by scanning SEMA4D stained whole tumors with antibodies directed against a different epitope than that recognized by Ab 67 and analyzing Sema4D distribution. Sections from 9 (control Ig) or 10 (anti-SEMA4D Ab 67) treated mice per group were used for analysis.
[0214] Colon 26 tumor cells expressed low levels of SEMA4D when cultured in vitro, but upregulated SEMA4D at the leading edge of the tumor in vivo. This resulted in the establishment of a high-concentration SEMA4D expression gradient at the tumor periphery. Treatment with anti-SEMA4D antibodies neutralized SEMA4D and disrupted this expression gradient. This resulted in significant changes in macrophage migration and distribution, as shown in Figure 2. Figure 4A Specifically, tumors treated with anti-SEMA4D Ab 67 had higher levels of M1+ pro-inflammatory macrophages at the leading edge of the tumor, as shown in Figure 5. Figure 4B The increase in M1+ macrophages was statistically significant. Tumors treated with anti-SEMA4D Ab 67 also showed a decrease in the frequency of tumor-promoting M2 macrophages at the leading edge of the tumor, as shown in Figure 6. Figure 4C These findings show that treatment with anti-SEMA4D Ab 67 alters macrophage distribution in a manner that increases the density of tumor suppressive macrophages (i.e., M1) at the tumor leading edge while decreasing the presence of tumor promoting macrophages (i.e., M2) in the same area. In addition, these findings show an overall increase in the density of CD8+ T cells within tumors isolated from MAb 67-treated mice, as shown in Figure 5. Figure 4D These findings suggest that neutralization of SEMA4D with MAb 67-2 drives anti-tumor M1 macrophages into the highly proliferative tumor cell zone and CD8+ T cells through this zone and into the leading edge (inset).
[0215] Example 5: Testing the ability of anti-SEMA4D antibodies to delay tumor growth in mice when used in combination with anti-CTLA4 antibodies
[0216] Experimental design. 5x10 5Colon 26 tumor cells were implanted subcutaneously in the axilla of female Balb / c mice. Treatment (50 mg / kg, IP, 5 times per week) with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2, with or without anti-CTLA4 / MAb UC10-4F10-11 (100 μg on day 8, 50 μg on days 11 and 14 after tumor inoculation) was started 1 day after inoculation. Treatment with anti-PD1 / RMP1-14 (100 μg on day 3, 2 times per week) in combination with anti-CTLA4 / MAb UC10-4F10-11 was started 1 day after inoculation. There were 20 mice in each group. Tumors were measured twice a week with a caliper starting 5 days after implantation. When tumor volume reached 1000mm 3 Animals were killed at that time.
[0217] The combination of anti-SEMA4D and anti-CTLA4 antibodies delayed tumor growth in mice. Tumor growth was measured with a caliper and the measurements were used to calculate the formula (w 2 Tumor volume was calculated by averaging 1000 mm x 1) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Mean tumor volume and Kaplan-Meier survival curves were determined over time until the endpoint, where tumor volume = 1000 mm 3 , respectively Figure 5A and 5B As shown. Statistical analysis was performed using two-phase analysis of variance (ANOVA) and log-rank analysis, respectively, which showed statistically significant treatment effects with anti-SEMA4D antibody (9% tumor growth delay, TGD**) and anti-CTLA4 antibody (2% TGD.ns), as well as a highly significant increase in tumor growth delay with the combination of anti-SEMA4D and anti-CTLA4 antibodies (maximum TGD, 114%****). The response can last for at least 60 days.
[0218] The frequency of tumor regression in the Colon 26 tumor model was also determined. Regression was the absence of palpable tumor, defined as a tumor measuring <50 mm 3 , based on at least 2 consecutive measurements. Figure 5CAs shown, the combination of anti-SEMA4D and anti-CTLA4 antibodies increased the number of regressions in the Colon 26 tumor model. As determined by Fisher's exact test, the regressions of the combination treatment (anti-SEMA4D + anti-CTLA4 antibody) were statistically significant compared to control Ig (p < 0.0001) and anti-CTLA4 or anti-SEMA4D monotherapy (p = 0.0022). Importantly, these findings show that the combination of anti-SEMA4D and anti-CTLA4 antibodies is synergistic: that is, the combination is significantly more effective than treatment with anti-SEMA4D antibody or anti-CTLA4 antibody alone, resulting in an increased frequency of sustainable tumor regressions. In addition, these results demonstrate that the combination of anti-SEMA4D and anti-CTLA4 antibodies is at least as effective as, or more effective than, the combination of anti-PD1 and anti-CTLA4.
[0219] It has also been demonstrated that treatment with anti-SEMA4D antibodies increases tumor reactive CTL activity, and also increases anti-CTLA4-mediated CTL activity. Follow-up studies were conducted to examine the effects of anti-CTLA monotherapy on the frequency of tumor-specific tumor infiltrating lymphocytes (TILs) and proinflammatory cytokine secretion compared to anti-CTLA4 and anti-SEMA4D combined therapy. In this follow-up study, immune cells were isolated from the spleen and tumor of mice carrying colon 26 tumors treated in vivo with a combination of control IgG1 / MAb2B8, anti-CTLA4 / MAbUC10-4F10, or anti-CTLA4 / MAbUC10-4F10 and anti-SEMA4D / MAb67. Tissue was harvested on the 15th day, which was 1 day after the last anti-CTLA4 antibody dose and just before tumor regression. Total CD45+ TILs were evaluated for secreted cytokine levels, and the frequency of IFNg-secreting CD8+ T cells in the presence of MHC-I-restricted Colon 26 tumor-specific immunodominant gp70 peptide was determined by ELISPOT. The frequency of MHC I-specific responses was calculated by subtracting vehicle controls from wells containing peptide.
[0220] like Figure 5D As shown, increased levels of the proinflammatory cytokine IFNg were observed in tumors of mice treated with anti-CTLA4 antibody monotherapy (p=0.0135), which were further and significantly enhanced after treatment with the combination therapy of anti-CTLA4 and anti-SEMA4D (p=0.0002 compared to control or monotherapy). Figure 5EIn the present study, an increased peptide-specific IFNg secretion response frequency was observed in the spleen of mice treated with anti-CTLA4 antibodies. This finding is expected because anti-CTLA4 has been reported to induce peripheral T cell activation. It was not found that the combination treatment of anti-CTLA4 and anti-SEMA4D further enhanced the activity in the spleen. On the contrary, a significant increase in the peptide-specific IFNg secretion response frequency was observed in TIL after treatment with anti-CTLA4 monotherapy, which was further significantly enhanced after treatment with anti-CTLA4 and anti-SEMA4D combination therapy. This finding shows that the addition of anti-SEMA4D treatment can significantly improve tumor-specific CD8+T cell activity in a local tumor-specific manner.
[0221] Example 6: Testing the ability of anti-SEMA4D antibodies to affect tumor infiltration of tumor-specific cytotoxic CD8+ T cells
[0222] MAb 67-2 treatment increased the frequency of tumor-specific TILs and the secretion of proinflammatory cytokines. After 4 weeks of in vivo anti-SEMA4D treatment, tumors were dissociated by magnetic separation and CD45+ cells were enriched. CD45+TILs collected from 5 mice were incubated at various cell densities in the presence and absence of the dominant immuno-tumor peptide AH-1. IFNγ secreting cells were measured by ELISPOT; peptide-specific responses were determined by subtracting the mean value of wells without peptides. Each sample was tested 6 times and plotted as above. Mann-Whitney nonparametric t-test was used to determine statistical significance.
[0223] Fig. 6A It is shown that an increase in IFNγ-secreting cells was observed in MAb 67-treated mice in the presence or absence of peptide.CD45+TILs, especially MHC-I-restricted peptide-specific CD8+ cytotoxic T cells, evolved into activated effector cells after treatment with MAb 67-2. Figure 6B Representative ELISPOT images are shown. CD45+ TILs were then cultured ex vivo for 48 hours and tested for cytokine secretion using CBA analysis. Figure 6C As shown, Mab 67-2 promoted the secretion of anti-tumor cytokines, such as IFNγ and TNFα, in TILs. Statistical significance was determined using the Mann-Whitney nonparametric t-test.
[0224] Follow-up studies were performed to examine the effects of MAb 67-2 treatment on the frequency of tumor-specific tumor-infiltrating lymphocytes (TILs) and the secretion of proinflammatory cytokines. In this follow-up study, immune cells were isolated from tumors of mice bearing Colon 26 tumors treated in vivo with control IgG1 / MAb2B8 or anti-SEMA4D / MAb67. The secreted cytokine levels of total CD45+TILs were evaluated, and the frequency of IFNg-secreting CD8+T in the presence of MHC-I-restricted Colon 26 tumor-specific immune-dominant gp70 peptides was determined by ELISPOT. The frequency of MHC I-specific responses was calculated by subtracting the medium control from the wells containing the peptide.
[0225] like Fig.6D As shown in Figure 5, increased levels of proinflammatory cytokines IFNg and TNFa were observed in TILs of mice treated with anti-SEMA4D antibody. Figure 5E As shown, an increased frequency of peptide-specific IFNg secretion responses was observed in TILs of mice treated with anti-SEMA4D antibodies. This finding suggests that the addition of anti-SEMA4D treatment can significantly improve tumor-specific CD8+ T cell activity in a local tumor-specific manner.
[0226] Example 7: Testing the ability of anti-SEMA4D antibodies to delay tumor growth in mice when used in combination with anti-PD1 antibodies
[0227] Experimental design. 5x10 5 Colon 26 tumor cells were implanted subcutaneously in the axilla of female Balb / c mice. Treatment with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, IP, once a week) began 1 day after inoculation. Groups of mice were also treated with control rat-Ig or rat anti-PD1 / MAb RMP1-14 (100 μg, twice a week, for 2 weeks starting 3 days after inoculation). There were 20 mice in each group. Tumors were measured 3 times a week with a caliper starting 5 days after implantation. When the tumor volume reached 1000 mm 3 Animals were killed at that time.
[0228] The combination of anti-SEMA4D and anti-PD1 antibodies delayed tumor growth in mice. Tumor growth was measured with a caliper and the measurements were used to calculate the formula (w 2 Tumor volume was calculated by averaging 1000 mm x 1) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Mean tumor volume and Kaplan-Meier survival curves were determined over time until the endpoint, where tumor volume = 1000 mm 3 , respectively Fig. 7A and 7BAs shown. Statistical analysis was performed using two-way analysis of variance (ANOVA) and log-rank analysis, respectively, which showed a statistically significant treatment effect of the combination of anti-SEMA4D antibody and anti-PD1 antibody in Balb / c mice. These findings show that the combination of anti-SEMA4D and anti-PD1 antibodies is more effective than treatment with anti-SEMA4D or anti-PD1 antibodies alone.
[0229] The frequency of regressions in the Colon 26 tumor model was also measured and Figure 7C and 7D Regression is the absence of palpable tumor, defined as tumor measuring <50 mm 3 , based on at least 2 consecutive measurements. The combination of anti-SEMA4D and anti-PD1 antibodies increased the number of regressions in the Colon 26 tumor model. The regressions of the combination treatment (αSEMA4D + αPD1 antibody) were statistically significant compared to control Ig (p = 0.0083) or single agent anti-PD-1 (p = 0.02) as determined by Fisher's exact test.
[0230] Example 8: Testing the ability of anti-SEMA4D antibodies to delay tumor growth in mice when combined with cyclophosphamide
[0231] Experimental design. 5x10 5 Colon 26 tumor cells were implanted subcutaneously in the axilla of female Balb / c mice. Treatment with control mouse IgG1 / 2B8 or anti-SEMA4D / MAb 67-2 (50 mg / kg, IP, once a week) was started 1 day after inoculation. Cyclophosphamide treatment (50 mg / kg, IP) was given on days 12 and 20. There were 20 mice in each group. Tumors were measured 3 times a week starting 5 days after implantation with a caliper. When the tumor volume reached 1000 mm 3 Animals were killed at that time.
[0232] The combination of anti-SEMA4D antibody and cyclophosphamide delayed tumor growth in mice. Tumor growth was measured with a caliper and the measurements were used to calculate the formula (w 2 Tumor volume was calculated by quantifying the tumor volume as xl) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Mean tumor volume, median tumor volume, and Kaplan-Meier survival curves were determined over time until the endpoint, where tumor volume = 1000 mm 3 , respectively Fig. 8A , 8B Statistical analysis was performed using two-way analysis of variance (ANOVA) and log-rank analysis, respectively, which showed a statistically significant treatment effect of the combination of anti-SEMA4D antibody and cyclophosphamide in Balb / c mice.
[0233] Specifically, the findings showed a 232% tumor growth delay (TGD) when anti-SEMA4D antibody was used in combination with cyclophosphamide. This finding was statistically significant (p < 0.0001) compared to control Ig as determined by MC log-rank analysis. There was also a 3% TGD when anti-SEMA4D antibody was used alone (statistically significant (p = 0.0282) compared to control Ig) and a 96% TGD when cyclophosphamide was used alone (statistically significant (p < 0.0001) compared to control Ig) as determined by MC log-rank analysis. The response could last for at least 81 days. These findings show that the combination of anti-SEMA4D antibody and cyclophosphamide is more effective in delaying tumor growth than treatment with anti-SEMA4D antibody or cyclophosphamide alone.
[0234] The frequency of regressions in the Colon 26 tumor model was also measured and Fig.8D and 8E Regression is the absence of palpable tumor, defined as tumor measuring <50 mm 3 , based on at least 2 consecutive measurements. The combination of anti-SEMA4D antibody and cyclophosphamide increased the number of regressions in the Colon 26 tumor model. As determined by Fisher's exact test, the regressions of the combination treatment (αSEMA4D antibody + cyclophosphamide) were statistically significant (p < 0.003) compared to control Ig. These data demonstrate that cyclophosphamide has increased efficacy and response when combined with anti-SEMA4D antibodies.
[0235] Example 9: Testing the ability of anti-SEMA4D antibodies to delay tumor growth in mice when used in combination with anti-HER2 / neu antibodies
[0236] Experimental design. 3x10 4 Tubo.A5 tumor cells were implanted subcutaneously in the mammary fat pad of female Balb / c mice. Treatment with control mice IgG1 / 2B8.1E7 or anti-SEMA4D / MAb 67-2 (50 mg / kg, IP, 6 times per week) was started 7 days after inoculation. Treatment with anti-Neu / MAb7.16.4 (200 μg, IP, 2 times per week, from tumors with a volume of approximately 200 mm 3 Each group had 15 mice. Tumors were measured twice a week with a caliper starting from day 11 after implantation. When the tumor volume reached 800 mm 3 Animals were killed at that time.
[0237] The combination of anti-SEMA4D and anti-HER2 / Neu antibodies delayed tumor growth in mice. Tumor growth was measured with a caliper and the measurements were used to calculate the formula (w 2Tumor volume was calculated by averaging 100 μg / cm2 (xl) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Mean tumor volume and Kaplan-Meier survival curves were determined over time until the endpoint, where tumor volume = 800 mm 3 , respectively Fig.9A and 9B As shown. Statistical analysis was performed using two-way analysis of variance (ANOVA) and log-rank analysis, respectively, which showed a statistically significant treatment effect of the combination of anti-SEMA4D antibody and anti-Her2 / Neu antibody in Balb / c mice. The findings showed that there was a 48% tumor growth delay when anti-SEMA4D antibody was used in combination with anti-Neu antibody, and this was statistically significant compared to the use of an irrelevant control antibody (p=0.017) or anti-Neu monotherapy (p=0.006), as determined by MC log-rank analysis.
[0238] The frequency of tumor regression in the Tubo tumor model was also measured and is shown in Fig. 9C Regression is the absence of palpable tumor, defined as tumor measuring <50 mm 3 , based on at least 2 consecutive measurements. The combination of anti-SEMA4D and anti-Neu antibodies increased the number of regressions in Tubo-bearing mice. The regressions of the combination treatment (αSEMA4D+αNeu antibody) were statistically significant (p=0.016) compared to control Ig as determined by Fisher's exact test.
[0239] Example 10: Testing the ability of anti-SEMA4D antibodies to delay growth in an in vivo breast cancer model
[0240] Experimental design. 3x10 4 Tubo.A5 tumor cells were implanted subcutaneously in the mammary fat pad of female Balb / c mice. Treatment with control mice IgG1 / 2B8.1E7 or anti-SEMA4D / MAb 67-2 (50 mg / kg, IP, 6 times per week) was started 6 days after inoculation. There were 20 mice in each group, however, some mice were excluded from the analysis due to premature death due to ulcers or general illness before reaching the endpoint. Tumors were measured twice a week with a caliper starting 13 days after implantation. When the tumor volume reached 800mm 3 Animals were killed at that time.
[0241] Anti-SEMA4D antibody treatment delayed tumor growth in mice. Tumor growth was measured with calipers and the measurements were used to calculate the formula (w 2Tumor volume was calculated by averaging 100 μg / cm2 (xl) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Mean tumor volume and Kaplan-Meier survival curves were determined over time until the endpoint, where tumor volume = 800 mm 3 , respectively Fig. 10A and 10B As shown. Statistical analysis was performed using two-way analysis of variance (ANOVA) and log-rank analysis, respectively, which showed a statistically significant treatment effect using anti-SEMA4D antibody. The findings showed the greatest tumor growth delay (133%) with anti-SEMA4D antibody treatment; this was statistically significant compared to the use of an irrelevant control antibody (p < 0.0001), as determined by MC log-rank analysis.
[0242] The frequency of tumor regression in the Tubo.A5 tumor model was also measured and is shown in Figures 10C-10E Regression is the absence of palpable tumor, defined as tumor measuring <50 mm 3 , based on at least 2 consecutive measurements. At day 90 post-implantation, 85% (12 / 14) of MAb67-treated mice were tumor-free regressors, and one of 14 never developed a measurable tumor, compared to 0 / 14 regressions in mice treated with control Ig. Mice that had completely eliminated their primary tumors (13 / 14 in MAb67-treated mice) were challenged with active Tubo.A5 (30,000) on the contralateral side on day 90; naive mice were included for use as transplant controls. Fig. 10D As shown, all 13 mice treated with anti-SEMA4D were protected from subsequent tumor challenge, indicating an immune memory response, consistent with Fig.10E The contrast is shown for naive mice that were not excluded from tumor challenge. The frequency of regressions compared to control Ig was statistically significant (p<0.0001) as determined by Fisher's exact test.
[0243] Example 11: Effect of anti-SEMA4D antibody on MDSC and T cell infiltration in Tubo.A5 tumor model
[0244] Experimental design. Tubo.A5 tumors were implanted in syngeneic BALB / c mice. Treatment with control Ig or anti-SEMA4D MAb 67 (50 mg / kg, IP, once a week) was started on day 6. Tumors were harvested on day 39, just before tumor regression. FACS was performed on lymphocyte fractions collected from tumors of 14-21 mice / group. Mean values of experimental replicates are shown; significance was determined using a two-tailed t-test.
[0245] like Fig.11A and 11BAs shown, anti-SEMA4D antibody treatment increased CD3+ T cell infiltration and reduced CD11b+Grl+MDSC in tumors of mice treated with anti-SEMA4D. These data indicate an increase in anti-tumorigenic T cell responses and a decrease in immunosuppressive cells such as MDSC. These data are consistent with the regulation of immune balance observed in the Colon 26 model.
[0246] Example 12: Dose Titration of Mab 67 in Tubo.A5 and Colon 26 Tumor Models
[0247] Experimental design of Tubo.A5 tumor model. 3x10 4 Tubo.A5 tumor cells were implanted subcutaneously in the mammary fat pad of female Balb / c mice. Treatment with control mice IgG1 / 2B8.1E7 (50 mg / kg, IP 6 times per week) or anti-SEMA4D / MAb 67-2 (1, 10 or 50 mg / kg, IP, 6 times per week) was started 6 days after inoculation. There were at least 20 mice in each group, however, some mice were excluded from the analysis due to premature death due to ulcers or general illness before reaching the endpoint. Tumors were measured twice a week with a caliper starting 13 days after implantation. When the tumor volume reached 800mm 3 Animals were killed at that time.
[0248] Experimental design of the Colon 26 tumor model. 5x10 5 Colon 26 tumor cells were implanted subcutaneously in the axilla of female Balb / c mice. Treatment was started 1 day after inoculation with control mouse IgG1 / 2B8.IE7 (50 mg / kg, IP, 5 times per week) or anti-SEMA4D / MAb67-2 (0.3, 3, 10, or 50 mg / kg, IP, 5 times per week), with or without anti-CTLA4 / MAb UC10-4F10-11 (100 μg-5 mg / kg on day 8 and 50 μg-2.5 mg / kg on days 11 and 14 after tumor inoculation). There were 15 mice per group. Tumors were measured twice a week with a caliper starting 5 days after implantation. When tumor volume reached ≥1000 mm 3 Animals were killed at that time.
[0249] The minimum effective dose was approximately 3 mg / kg. Treatment of Tubo.A5 tumors with 50 or 10 mg / kg MAb67 resulted in statistically significant tumor growth delay compared to control IgG (p<0.0001 and dp=0.0015, respectively), but were not significantly different from each other. The frequencies of regressions of 38% (9 / 24) and 54% (6 / 13) in Tubo.A5 tumors treated with 50 or 10 mg / kg MAb67 were also significant (p=0.0069 and p=0.0014, respectively). In contrast, 1 mg / kg Mab67 was ineffective and did not significantly delay tumor growth (p=0.01441). In this model, the minimum effective dose was determined to be 1 to 10 mg / kg. Tumor growth was measured with a caliper and the measurements were used to calculate the regression rate using the formula (w 2 Tumor volume was calculated by averaging 100 μg / cm2 (xl) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Mean tumor volume and Kaplan-Meier survival curves were determined over time until the endpoint, where tumor volume = 800 mm 3 , respectively Fig. 12A and 12B Statistical analysis was performed using two-way analysis of variance (ANOVA) and log-rank analysis, respectively.
[0250] Further refinement of the effective Mab67 dose was investigated in the Colon 26 model and determined to be ≥3 mg / kg. Treatment of Colon 26 tumors with anti-CTLA4 + anti-SEMA4D resulted in the greatest tumor growth delay (119%) when the dose of anti-SEMA4D / MAb 67 was ≥3 mg / kg compared to anti-CTLA4 monotherapy; p=0.0101 at 10 mg / kg MAb67 and p=0.0571 at 3 mg / kg compared to anti-CTLA1 monotherapy, determined using MC log-rank analysis. All doses between 3-50 mg / kg were not significantly different from each other. In contrast, when anti-CTLA4 was given in combination with 0.3 mg / kg MAb67, the difference was statistically different compared to treatment with 10 mg / kg MAb 67 (p=0.0325), but was not significantly different compared to anti-CTLA4 monotherapy (p=0.4945). Tumor growth was measured with calipers and the measurements were used to calculate the formula (w 2 Tumor volume was calculated by averaging 1000 mm x 1) / 2, where w = width of the tumor, the smaller measurement and l = length of the tumor in mm. Mean tumor volume and Kaplan-Meier survival curves were determined over time until the endpoint, where tumor volume = 1000 mm 3 , respectively Fig. 12C and 12D Statistical analysis was performed using two-way analysis of variance (ANOVA) and log-rank analysis, respectively.
[0251] Example 13: Effect of anti-SEMA4D antibodies on delayed tumor growth in Colon 26 and Tubo.A5 tumor models
[0252] Experimental design. Fig.13 is a summary of the experiments performed in the above examples showing tumor regression and growth following tumor re-challenge in the Colon 26 and Tubo.A5 tumor models. The experimental design of each experiment is summarized in the above examples.
[0253] Anti-SEMA4D antibody treatment resulted in complete and sustainable tumor regression. Fig.13 As shown, treatment with anti-SEMA4D antibody therapy resulted in a statistically significant increase in tumor regression, 7% (P≤0.001***) and 85% (P≤0.0001****) when compared to treatment with control mouse IgG1 in the Colon 26 and Tubo.A5 models, respectively. In addition, treatment with anti-SEMA4D antibody therapy was not significantly different from anti-PD1 treatment alone (7% with anti-SEMA4D alone vs. 8% with anti-PD1 alone, ns), but was significantly enhanced when combined with anti-PD1 treatment (28% of the combination therapy vs. 7% of anti-SEMA4D monotherapy or 8% of anti-PD1 monotherapy, P≤0.0001****). In addition, treatment with anti-SEMA4D antibody therapy combined with anti-CTLA4 therapy resulted in a statistically significant increase in tumor regression compared to anti-CTLA4 treatment alone (74% of the combination therapy vs. 20% of anti-CTLA4 monotherapy, P≤0.0001****). In addition, compared with anti-SEMA4D and anti-PD1 combination treatment, the combination treatment with anti-SEMA4D antibody therapy and anti-CTLA4 therapy resulted in a statistically significant increase in tumor regression (74% of anti-SEMA4D / anti-CTLA4 combination treatment vs. 60% of anti-SEMA4D / anti-PD1 combination treatment, P≤0.001****). The greater apparent synergy of the combination of anti-SEMA4D and anti-CTLA4 compared to the combination of anti-SEMA4D and anti-PD1 indicates that not all immune checkpoint blockade inhibitors are equivalent in this regard and that the difference in mechanism may be associated with different therapeutic benefits. Finally, compared with cyclophosphamide treatment alone, the combination treatment with anti-SEMA4D antibody therapy and cyclophosphamide resulted in a statistically significant increase in tumor regression (40% of the combination treatment vs. 10% of the cyclophosphamide monotherapy, P≤0.01****).
[0254] Through the above description and the contents shown in the relevant figures, many improvements and other embodiments of the present invention can be imagined by those skilled in the art of the present invention. Therefore, it should be understood that the present invention is not limited to the specific embodiments disclosed, and the improvements and other embodiments are also included in the scope of the attached claims and the listed embodiments. Although specific terms are used in the present invention, these terms are only used in a general and descriptive sense and are not used to limit the present invention.
Claims
1. Use of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and at least one other immunomodulatory therapeutic agent in the preparation of a medicament for inhibiting, delaying or reducing tumor growth in a patient with colon cancer, wherein the anti-SEMA4D antibody or fragment thereof comprises a variable heavy chain (VH) and a variable light chain (VL), wherein the variable heavy chain comprises VHCDR1-3 consisting of SEQ ID NOs: 6, 7 and 8, respectively, and the variable light chain comprises VLCDR1-3 consisting of SEQ ID NOs: 14, 15 and 16, respectively, and the at least one other immunomodulatory therapeutic agent is selected from an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody or antigen-binding fragment thereof, an anti-programmed cell death 1 (PD-1) antibody or antigen-binding fragment thereof, and cyclophosphamide; and wherein the medicament provides enhanced therapeutic efficacy relative to the anti-SEMA4D antibody or fragment thereof alone or the at least one other immunomodulatory therapeutic agent alone.
2. The use of claim 1, wherein the anti-SEMA4D antibody or fragment thereof and the at least one immunomodulatory therapeutic agent are formulated for separate administration.
3. The use of claim 1, wherein the anti-SEMA4D antibody or fragment thereof and the at least one immunomodulatory therapeutic agent are formulated for simultaneous administration.
4. The method of claim 1, wherein VH and VL comprise SEQ ID NO: 9 and SEQ ID NO: 17 or SEQ ID NO: 10 and SEQ ID NO: 18, respectively.
5. Use of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an anti-HER2 / Neu antibody in the preparation of a medicament for inhibiting, delaying or reducing tumor growth in a patient with breast cancer, wherein the anti-SEMA4D antibody or fragment thereof comprises a variable heavy chain (VH) and a variable light chain (VL), wherein the variable heavy chain comprises VHCDR1-3 consisting of SEQ ID NOs: 6, 7 and 8, respectively, and the variable light chain comprises VLCDR1-3 consisting of SEQ ID NOs: 14, 15 and 16, respectively; and wherein the medicament provides enhanced therapeutic efficacy relative to the anti-SEMA4D antibody or fragment thereof alone or the anti-HER2 / Neu antibody alone.
6. The use according to claim 5, wherein the anti-SEMA4D antibody or fragment thereof and the anti-HER2 / Neu antibody are formulated for separate administration.
7. The use according to claim 5, wherein the anti-SEMA4D antibody or fragment thereof and the anti-HER2 / Neu antibody are formulated for simultaneous administration.
8. The use of any one of claims 1-7, wherein the colon cancer patient or breast cancer patient has elevated levels of circulating B cells, T cells, or both B cells and T cells compared to other solid tumor patients.
9. The use according to claim 8, wherein the level of B cells and / or T cells per microliter of blood in the colon cancer patient or breast cancer patient is 1.5 to 5 times the average number of B cells and / or T cells in the circulation of other solid tumor patients.
10. The use according to claim 8, wherein the colon cancer patient or breast cancer patient has a level of B cells and / or T cells that falls within or above the range of B cells and / or T cells of a healthy individual.
11. The use according to any one of claims 1 to 7, wherein the anti-SEMA4D antibody or fragment thereof inhibits the interaction of SEMA4D with its receptor.
12. The use according to claim 11, wherein the receptor is Plexin-B1.
13. The use according to claim 12, wherein the anti-SEMA4D antibody or fragment thereof inhibits SEMA4D-mediated Plexin-B1 signal transduction.
14. The method of claim 5, wherein VH and VL comprise SEQ ID NO: 9 and SEQ ID NO: 17 or SEQ ID NO: 10 and SEQ ID NO: 18, respectively.
15. The use according to claim 5, wherein the breast cancer expresses Her2 and Plexin B1 or Plexin B2.
Citation Information
Patent Citations
Optimized Fc variants and methods for their generation
US20040132101A1
Use of anti-cd100 antibodies
US20060233793A1
Covalent diabodies and uses thereof
US20070004909A1
Human Anti-CD100 antibodies
US20080219971A1
Anti-CD100 Neutralizing Antibodies and Methods of Using the Same
US20100285036A1
